var title_f20_49_21264="Telangiectasia in scleroderma";
var content_f20_49_21264=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Telangiectasias in scleroderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Telangiectasias in a patient with limited cutaneous systemic sclerosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_49_21264=[""].join("\n");
var outline_f20_49_21264=null;
var title_f20_49_21265="Manual hematocrit";
var content_f20_49_21265=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Manual (spun) hematocrit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 248px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo shows two anticoagulated blood-filled Wintrobe hematocrit tubes following high speed centrifugation. The tube on the left is from a normal subject, with a hematocrit of 38 percent (blue arrow). The tube on the right is from a 19-year-old female with essential thrombocytosis and a platelet count of 5,000,000/microL. The extreme degree of thrombocytosis can be appreciated by the presence of a marked increase in the size of the \"buffy coat\" (white arrow). When the Wintrobe tube is filled to near capacity (upper arrows), the platelet count can be estimated by the thickness of this layer, with each mm being equivalent to one million platelets/microL. In normal subjects, the buffy coat, which is comprised of white blood cells and platelets, is only minimally visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen A Landaw, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_49_21265=[""].join("\n");
var outline_f20_49_21265=null;
var title_f20_49_21266="Pulmonary embolism IE";
var content_f20_49_21266=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of a patient with tricuspid valve endocarditis due to S. aureus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note multiple cavitating lung nodules due to septic pulmonary emboli.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Phillip Goodman, MD. Duke University Medical Center.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_49_21266=[""].join("\n");
var outline_f20_49_21266=null;
var title_f20_49_21267="Sodium nitrite: Patient drug information";
var content_f20_49_21267=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sodium nitrite: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"     see \"Sodium nitrite: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F14727716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe red blood cell problems may happen. People with more chance of getting these problems may have an enzyme deficiency called G6PD deficiency.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe low blood pressure may happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F14727718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691802",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cyanide poisoning.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F14727717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3852803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sodium nitrite or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F14727721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697168",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have anemia, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F14727722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14727723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F14727720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F14727724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86036 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_49_21267=[""].join("\n");
var outline_f20_49_21267=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14727716\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14727718\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14727717\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14727721\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14727722\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14727723\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14727720\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14727724\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=related_link\">",
"      Sodium nitrite: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_49_21268="Water manometer for pleural pressure measurement 22G needle";
var content_f20_49_21268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Water manometer for pleural pressure measurement: 22G needle interposed",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An illustration of the interposed 22-gauge (G) needle for the water manometer. Both IV tubes must be carefully purged of air prior to acquiring pleural pressures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The American College of Chest Physicians. Doelken P, Huggins JT, Pastis NJ, Sahn SA. Pleural manometry: technique and clinical implications. Chest 2004; 126:1764. Copyright &copy; 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_49_21268=[""].join("\n");
var outline_f20_49_21268=null;
var title_f20_49_21269="Rabies virus vaccine: Pediatric drug information";
var content_f20_49_21269=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rabies virus vaccine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"    see \"Rabies virus vaccine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/33/10769?source=see_link\">",
"    see \"Rabies virus vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Imovax&reg; Rabies;",
"     </li>",
"     <li>",
"      RabAvert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Imovax&reg; Rabies;",
"     </li>",
"     <li>",
"      RabAvert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F16144579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Postexposure prophylaxis:",
"     </b>",
"     All postexposure treatment should begin with immediate cleansing of the wound with soap and water (for ~15 minutes); immunization should begin as soon as possible after exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACIP Recommendations: I.M.: 1 mL/dose for 4 doses, on days 0, 3, 7, and 14;",
"     <b>",
"      Note:",
"     </b>",
"     Immunocompromised patients should receive a fifth dose on day 28. Administer rabies immune globulin (RIG) 20 international units/kg body weight around and into the wound(s) if anatomically feasible; administer any remaining volume of the RIG dose I.M. at a distant anatomical site (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"      see \"Rabies virus vaccine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants, Children, Adolescents, and Adults: I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pre-exposure prophylaxis:",
"     </b>",
"     1 mL/dose for 3 doses, on days 0, 7, and 21 or 28. Frequency of booster doses dependent upon rabies exposure risk and may include using antibody titers drawn every 6 months to 2 years to determine booster dose need.",
"     <b>",
"      Note:",
"     </b>",
"     Prolonging the interval between doses does not interfere with immunity achieved after the concluding dose of the basic series.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postexposure prophylaxis:",
"     </b>",
"     All postexposure treatment should begin with immediate cleansing of the wound with soap and water (for ~15 minutes); immunization should begin as soon as possible after exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Persons not previously immunized (ACIP Recommendation): 1 mL/dose for 4 doses, on days 0, 3, 7, and 14;",
"     <b>",
"      Note:",
"     </b>",
"     Immunocompromised patients should receive a fifth dose on day 28. Administer rabies immune globulin (RIG) 20 international units/kg body weight around and into the wound(s) if anatomically feasible; administer any remaining volume of the RIG dose I.M. at a distant anatomical site (CDC, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Persons who have previously received vaccine (either previous postexposure prophylaxis or pre-exposure series of vaccination) or have a previously documented rabies antibody titer considered adequate: 1 mL/dose on days 0 and 3; do not administer RIG",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imovax&reg; Rabies: 2.5 units [contains albumin (human), neomycin (may have trace amounts); HDCV; grown in human diploid cell culture; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     RabAvert&reg;: 2.5 units [contains albumin (human), amphotericin B (may have trace amounts), bovine gelatin, chicken egg protein, chlortetracycline (may have trace amounts), neomycin (may have trace amounts); PCEC; grown in chicken fibroblast culture; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M.: Reconstitute with provided diluent;",
"     <b>",
"      not for I.V. or SubQ administration;",
"     </b>",
"     administer injections in the deltoid muscle, not the gluteal; for infants and small children the outer aspect of the thigh may be used. Do not administer in same syringe as RIG. Adolescents and adults should be vaccinated while seated or lying down.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1061753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light; do not freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pre-exposure immunization: To provide protection against rabies virus to persons with unrecognized exposure or to those in areas where postexposure treatment would be delayed (FDA approved in all ages). Vaccinate persons with greater than usual risk due to occupation or avocation, including veterinarians, rangers, animal handlers, certain laboratory workers, and persons living in or visiting countries for longer than 1 month where rabies is a constant threat.",
"     <b>",
"      Note:",
"     </b>",
"     Routine pre-exposure prophylaxis for the general U.S. population or routine travelers to areas where rabies is not enzootic is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postexposure prophylaxis: To provide protection against rabies virus.  If a bite from a carrier animal is unprovoked or if the animal is not captured and rabies is present in that species and area, administer rabies immune globulin (RIG) and the vaccine as indicated (FDA approved in all ages)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F216842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Circulatory reactions, edema, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, encephalitis, fatigue, fever &gt;38&deg;C (100&deg;F), Guillain-Barr&eacute; syndrome, headache, malaise, meningitis, multiple sclerosis, myelitis, neuroparalysis, seizures, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, urticaria, urticaria pigmentosa",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Hematoma, limb swelling (extensive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, limb pain, monoarthritis, neuropathy, paralysis (transient), paresthesias (transient), weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Retrobulbar neuritis, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, dyspnea, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylaxis, hypersensitivity reactions, serum sickness, swollen lymph nodes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pre-exposure treatment: Hypersensitivity to any component; Imovax&reg; Rabies contains albumin and neomycin; RabAvert&reg; contains albumin, amphotericin B, bovine gelatin, chicken protein, chlortetracycline, and neomycin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postexposure treatment: Life-threatening allergic reactions to rabies vaccine or any components (carefully consider a patient's risk of rabies before continuing therapy)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with caution to patients with thrombocytopenia or any coagulation disorder that would be compromised by I.M. injection. Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate treatment for anaphylactic/anaphylactoid reaction should be available during administration of this vaccine. Once postexposure prophylaxis has begun, administration should generally not be interrupted or discontinued due to local or mild adverse events. Continuation of vaccination following severe systemic reactions should consider the person&rsquo;s risk of developing rabies. Report serious reactions to VAERS or the manufacturer/distributor. An immune complex reaction characterized by generalized urticaria, arthralgia, arthritis, angioedema, nausea, vomiting, fever, and malaise has been reported 2-21 days following booster doses of rabies vaccine. Immune response may be decreased in immunocompromised patients. Encephalitis, meningitis, and neuroparalytic events (eg, Guillain-Barr&eacute; syndrome, myelitis, retrobulbar neuritis) and multiple sclerosis have been temporally associated with use; careful consideration of a patient's risk of rabies should be assessed. Pre-exposure immunization does not eliminate the need for prompt prophylaxis following an exposure but does reduce the postexposure treatment regimen. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs. In general, household and close contacts of persons with altered immune competence may receive all age-appropriate vaccines. Products contain albumin and may carry a remote risk of transmitting Creutzfeldt-Jakob or other viral diseases.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: May diminish the therapeutic effect of Rabies Vaccine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F216820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Pregnancy is not a contraindication to postexposure prophylaxis. Pre-exposure prophylaxis during pregnancy may also be considered if risk of rabies is great.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum rabies antibody titers are not routinely recommended in postexposure patients unless the patient was immunocompromised; to determine the need for repeat booster treatment, titers may be measured every 6 months to 2 years in persons at high risk for exposure. Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rabies vaccine is an inactivated virus vaccine which promotes immunity by inducing an active immune response. The production of specific antibodies requires about 7-10 days. In postexposure, rabies immune globulin (RIG) or antirabies serum, equine (ARS) is administered in conjunction with rabies vaccine to provide immune protection until an antibody response can occur.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.M.: Rabies antibody: &sim;7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak effect: &sim;30-60 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &ge;1 year",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10285350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events.   If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines.  Separate needles and syringes should be used for each injection.  The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible. (CDC, 2011)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/49/21269/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Human Rabies Prevention - United States, 2008 Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2008, 57(RR-3):1-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/49/21269/abstract-text/18496505/pubmed\" id=\"18496505\" target=\"_blank\">",
"        18496505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/49/21269/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 2;57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/49/21269/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Use of a Reduced (4-Dose) Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-2):1-9. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/PDF/rr/rr5902.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/PDF/rr/rr5902.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/49/21269/abstract-text/20300058/pubmed\" id=\"20300058\" target=\"_blank\">",
"        20300058",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manning SE, Rupprecht CE, Fishbein D, et al, \"Human Rabies Prevention--United States, 2008: Recommendations of the Advisory Committee on Immunization Practices,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2008, 57(RR-3):1-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/49/21269/abstract-text/18496505/pubmed\" id=\"18496505\" target=\"_blank\">",
"        18496505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/49/21269/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/49/21269/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rupprecht CE, Briggs D, Brown CM, et al, \"Use of a Reduced (4-Dose) Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-2):1-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/49/21269/abstract-text/20300058/pubmed\" id=\"20300058\" target=\"_blank\">",
"        20300058",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12950 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-3384FBAA07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_49_21269=[""].join("\n");
var outline_f20_49_21269=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216827\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216828\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061757\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16144579\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061750\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216810\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216796\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061760\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061753\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061759\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216842\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061763\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061749\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061748\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299976\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216804\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216806\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216820\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061756\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061747\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061762\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10285350\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12950\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12950|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=related_link\">",
"      Rabies virus vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/33/10769?source=related_link\">",
"      Rabies virus vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_49_21270="Tinea versicolor shoulder PI";
var content_f20_49_21270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F58608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F58608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea versicolor on the shoulder and arm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tinea versicolor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_49_21270=[""].join("\n");
var outline_f20_49_21270=null;
var title_f20_49_21271="Prurigo nodularis 2";
var content_f20_49_21271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66268%7EDERM%2F53475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66268%7EDERM%2F53475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prurigo nodularis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple nodules, some of which excoriated, on the lower limb of a patient with nodular prurigo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prurigo nodularis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Discrete, excoriated nolules on the leg of a patient with nodular prurigo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_49_21271=[""].join("\n");
var outline_f20_49_21271=null;
var title_f20_49_21272="Defibrillation and cardioversion in children (including automated external defibrillation)";
var content_f20_49_21272=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Defibrillation and cardioversion in children (including automated external defibrillation)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/49/21272/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/49/21272/contributors\">",
"     Richard J Scarfone, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/49/21272/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/49/21272/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/49/21272/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/49/21272/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/49/21272/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defibrillation (DF) and cardioversion are methods of delivering electrical energy to the heart through the chest wall in an attempt to restore the heart's normal rhythm. Defibrillation and cardioversion may be accomplished using a manual defibrillator, which requires users to recognize the dysrhythmia and preselect the energy to be delivered. Alternatively, automated external defibrillators (AEDs) may be used. AEDs are computerized machines that automatically diagnose ventricular fibrillation (VF) and use voice prompts to instruct rescuers to defibrillate, if appropriate. In addition, based on preset values for heart rate and R-wave morphology, AEDs may advise defibrillation for ventricular tachycardia (VT).",
"   </p>",
"   <p>",
"    This topic will review the technique of electrical countershock, including AED use, in children. The basic principles that underlie countershock treatment; the clinical indications for these procedures and the side effects that may be seen; and the development, use, allocation, and efficacy of automated external defibrillators (AEDs) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link\">",
"     \"Basic principles and technique of cardioversion and defibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link\">",
"     \"Cardioversion for specific arrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=see_link\">",
"     \"Automated external defibrillators\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an important distinction between defibrillation and cardioversion:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Defibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defibrillation is the asynchronous delivery of energy, such as the shock is delivered randomly during the cardiac cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardioversion is the delivery of energy that is synchronized to the QRS complex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of children with cardiopulmonary arrest that are cared for by emergency department (ED) clinicians experience an out-of-hospital arrest and are apneic and pulseless on arrival to the ED. Most, but not all, of these children will have suffered a respiratory arrest leading to asystole [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], which is not amenable to treatment with electrical current [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/3\">",
"     3",
"    </a>",
"    ]. However, a recent retrospective study assessing children experiencing out-of-hospital, non-traumatic cardiopulmonary arrest found that about 18 percent had ventricular fibrillation (VF) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/4\">",
"     4",
"    </a>",
"    ]. The incidence of VF in children ages eight years and older was 27 percent; about four times greater than for younger children. In separate studies, VF was the initial rhythm in 9 percent and 19 percent of children experiencing out-of-hospital cardiac arrests, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. The implications of this experience for pediatric defibrillation are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children do experience VF [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Survival with VF is better than survival with asystole [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clinicians caring for children must be well-versed in the methods of countershock delivery since survival is directly correlated with minimizing the time to delivery of electrical current [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cardioversion is also an important treatment modality in children. Unstable supraventricular tachycardia constitutes the most common pediatric arrhythmia requiring cardioversion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link\">",
"     \"Management of supraventricular tachycardia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ANATOMY AND PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Located in the upper pole of the right atrium, the sinoatrial (SA) node serves as the site of initial electrical impulse (depolarization) during normal cardiac contraction. This wave of depolarization spreads through the atria, resulting in atrial contraction. It is then conducted in succession through the atrioventricular (AV) node, bundle of His, bundle branches, and Purkinje fibers to produce a timed and coordinated ventricular contraction (",
"    <a class=\"graphic graphic_figure graphicRef61989 \" href=\"UTD.htm?34/63/35827\">",
"     figure 1",
"    </a>",
"    ). Deflections on the electrocardiogram reflect the measurable portions of this wave of depolarization (",
"    <a class=\"graphic graphic_figure graphicRef59933 \" href=\"UTD.htm?1/61/2006\">",
"     figure 2",
"    </a>",
"    ) and correlate with cardiac activity (",
"    <a class=\"graphic graphic_figure graphicRef69079 \" href=\"UTD.htm?43/43/44726\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In patients with tachyarrhythmias or fibrillation, this normal conduction is disrupted. Electrical countershock attempts to reinstate normal cardiac depolarization and contraction. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Mechanism of action'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Anatomically, pads or electrodes are placed on the chest so that an adequate portion of the delivered shock passes through the myocardium. The",
"    <span class=\"nowrap\">",
"     anterior/apex",
"    </span>",
"    position requires less patient movement and is typically preferred (",
"    <a class=\"graphic graphic_figure graphicRef59094 \" href=\"UTD.htm?1/40/1671\">",
"     figure 4",
"    </a>",
"    ). However,",
"    <span class=\"nowrap\">",
"     anterior/posterior",
"    </span>",
"    pad or paddle placement is also acceptable (",
"    <a class=\"graphic graphic_figure graphicRef53963 \" href=\"UTD.htm?37/29/38356\">",
"     figure 5",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Electrode placement'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardioversion terminates arrhythmia by the delivery of a synchronized shock that depolarizes the tissue involved in a reentrant circuit. By depolarizing all excitable tissue of the circuit and making the tissue refractory, the circuit is no longer able to propagate or sustain reentry. As a result, cardioversion terminates those arrhythmias resulting from a single reentrant circuit, such as supraventricular tachycardia, atrial flutter, or monomorphic ventricular tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link&amp;anchor=H2#H2\">",
"     \"Basic principles and technique of cardioversion and defibrillation\", section on 'Electrophysiology of defibrillation and cardioversion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=see_link\">",
"     \"Reentry and the development of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Defibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite its wide use, there is still controversy concerning the electrophysiologic mechanisms by which electrical current terminates atrial or ventricular fibrillation, arrhythmias which involve multiple microreentrant circuits. Fibrillation involves the entire atrial or ventricular myocardium and is considered to be a very recalcitrant unstable rhythm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link\">",
"     \"The electrocardiogram in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\", section on 'Mechanism of VF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence suggests that a certain amount of myocardium must be available to sustain atrial or ventricular fibrillation and the entire myocardium must be uniformly depolarized in order to terminate the arrhythmia (critical mass hypothesis). However, the shock strength must also be greater than the largest shock that reinitiates fibrillation in vulnerable regions of the myocardium (the upper limit of vulnerability). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link&amp;anchor=H2#H2\">",
"     \"Basic principles and technique of cardioversion and defibrillation\", section on 'Electrophysiology of defibrillation and cardioversion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Shock delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-generation defibrillators were monophasic, delivering waveforms with one direction of current. Biphasic defibrillators invert the current direction in the last phase of the shock (",
"    <a class=\"graphic graphic_waveform graphicRef72878 \" href=\"UTD.htm?32/61/33757\">",
"     waveform 1",
"    </a>",
"    ). Compared with monophasic devices, biphasic units have a greater first shock efficacy and expose the heart to less peak current. Decreasing the energy level necessary for successful defibrillation decreases the risk of burns or myocardial damage. Most manufacturers have stopped making monophasic devices although there may be some still in use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link&amp;anchor=H11#H11\">",
"     \"Basic principles and technique of cardioversion and defibrillation\", section on 'Monophasic versus biphasic waveforms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regarding the frequency of electrical shocks, three stacked shocks in rapid succession are no longer recommended (",
"    <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"     algorithm 1",
"    </a>",
"    ). Older monophasic defibrillators had a low first-shock efficacy. Three stacked shocks were recommended to decrease impedance in an attempt to increase efficacy. Newer generation biphasic defibrillators have a first-shock efficacy approaching 90 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link&amp;anchor=H11#H11\">",
"     \"Basic principles and technique of cardioversion and defibrillation\", section on 'Monophasic versus biphasic waveforms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Failure of defibrillation after a first shock suggests that subsequent shocks in rapid succession are also likely to fail. In this setting, CPR is likely to be more beneficial so a single shock should be immediately followed by resumption of CPR, not a second shock. This approach will minimize interruptions of CPR associated with pulse checks and shock delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Coordination of shock delivery and chest compressions",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the American Heart Association (AHA) guidelines, patients who experience unwitnessed arrest should undergo two minutes of CPR prior to attempted defibrillation (",
"    <a class=\"graphic graphic_algorithm graphicRef66803 \" href=\"UTD.htm?17/38/18018\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link\">",
"     \"Basic life support in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are insufficient data to know whether or not CPR prior to defibrillation improves survival for in-hospital cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Guidelines from the AHA state that, \"healthcare providers who treat cardiac arrest in hospitals and other facilities with AEDs on-site should provide CPR and should use the",
"    <span class=\"nowrap\">",
"     AED/defibrillator",
"    </span>",
"    as soon as it is available\" [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/9\">",
"     9",
"    </a>",
"    ]. The logistics involved with mobilizing a defibrillator are such that typically CPR does precede defibrillation; however, a shock should be delivered as soon as possible after an in-hospital cardiac arrest and CPR should be resumed immediately after attempted defibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The AHA guidelines for pediatric basic and advanced life support also emphasize that chest compressions should be hard (eg, at least one-third of the anterior-posterior diameter of the chest) and fast (eg, 100 per minute). The rescuer should allow for complete chest recoil after a compression and minimize interruptions between compressions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=see_link\">",
"     \"Basic life support in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The application of electrical current is an essential component of advanced cardiopulmonary resuscitation (CPR) guidelines for the treatment of ventricular fibrillation (VF), ventricular tachycardia (VT), and unstable",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drug resistant organized cardiac rhythms, such as supraventricular tachycardia (",
"    <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"     algorithm 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Defibrillation is indicated in the treatment of the following: ventricular fibrillation and pulseless ventricular tachycardia.",
"     </li>",
"     <li>",
"      Cardioversion should be used in unstable patients with organized cardiac rhythms, such as supraventricular tachycardia (SVT), atrial fibrillation, atrial flutter, or ventricular tachycardia with a palpable pulse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The procedure for defibrillation and cardioversion are identical except that synchronized mode with a reduced dose of initial electricity is selected for cardioversion. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Machine operation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Defibrillation can be performed with an automated external defibrillator (AED) in children greater than one year old with VF or pulseless VT. AEDs do not deliver synchronized shocks and thus, cannot be used for cardioversion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS AND PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac rhythms that should not be treated with electrical current include sinus rhythm, stable SVT, asystole, pulseless electrical activity, and bradycardia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Rescuer and bystander safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk of electrical shock to a bystander or rescuer and fire are the two main safety issues related to the use of electrical countershock [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/11\">",
"     11",
"    </a>",
"    ]. Prior to electrical discharge, all bystanders and the rescuer should ensure that they are not in contact with the patient or the stretcher. In prehospital settings, the patient should be moved from wet, soaked ground or standing water before receiving electric countershock. Of note, reports of inadvertent shocks to bystanders have demonstrated only minor adverse outcomes, such as tingling in the involved extremity, transient lethargy, or minor burns [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, there are no reports of serious injury to lay responders who have used automated external defibrillators. Inappropriate electric countershock in a healthy person has been associated with serious morbidity and mortality.",
"   </p>",
"   <p>",
"    Sparks from hand-held defibrillator paddles have caused fires involving adjacent flammable materials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/11\">",
"     11",
"    </a>",
"    ]. This hazard can be reduced by using electrode pads instead of hand-held paddles for shock delivery and by ensuring that oxygen delivery devices are at least 1 m away from the patient during electric countershock. In addition, flammable alcohol pads should never be used as contact materials for defibrillation or cardioversion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As time allows, clinicians obtain patient history regarding conditions that may have led to the dysrhythmia or may influence the likelihood of success of defibrillation, such as known cardiac disease, current medications, or evidence of poisoning. The acquisition of additional medical history may have to be deferred until after defibrillation is performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Patient counseling/informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The emergent conditions under which defibrillation and emergent cardioversion is performed generally preclude the discussion of risks, benefits, and complications with the patient or family.",
"   </p>",
"   <p>",
"    However, the specific risks and benefits of cardioversion of stable rhythms should be provided to the child's caretaker prior to the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tables summarize the procedure for defibrillation (",
"    <a class=\"graphic graphic_table graphicRef50341 \" href=\"UTD.htm?10/12/10444\">",
"     table 1",
"    </a>",
"    ) and cardioversion (",
"    <a class=\"graphic graphic_table graphicRef74475 \" href=\"UTD.htm?17/41/18076\">",
"     table 2",
"    </a>",
"    ) and provide clinical tips for the use of a manual (",
"    <a class=\"graphic graphic_table graphicRef79418 \" href=\"UTD.htm?24/41/25244\">",
"     table 3",
"    </a>",
"    ) or automated (",
"    <a class=\"graphic graphic_table graphicRef74523 \" href=\"UTD.htm?33/7/33915\">",
"     table 4",
"    </a>",
"    ) defibrillator. The algorithms indicate recommended rhythms, dosing, and adjunct treatments for the use of defibrillation and cardioversion in children (",
"    <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"     algorithm 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Analgesia and sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with VF or pulseless VT are unconscious and do not require sedation or analgesia. In contrast, patients requiring synchronized cardioversion may be awake and responsive to pain. Unless they are too unstable to delay the cardioversion, they should receive medications that will provide an appropriate level of sedation and analgesia prior to cardioversion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to defibrillation, clinical assessment of the adequacy of cardiopulmonary resuscitation (CPR) may be determined by noting breath sounds and chest wall rise and palpating distal pulses during compressions. If appropriate, confirmation of proper endotracheal tube position is made by noting the depth of insertion at the lips and listening for equal breath sounds bilaterally. The pulse and blood pressure of conscious patients needing cardioversion should be assessed frequently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Methods: Manual defibrillator use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful delivery of an electric countershock relies on the selection of the proper electrodes, conductors, and energy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Electrode choice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians may use either handheld paddles or self-adhesive electrode pads to defibrillate or cardiovert. Electrode pads offer several advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They can be used to monitor the heart rhythm without the need for additional electrocardiogram electrodes that may interfere with pad placement (although paddles often have monitoring capabilities, as well).",
"     </li>",
"     <li>",
"      Creams or gels are not needed, making arcing of electrical current across the chest unlikely.",
"     </li>",
"     <li>",
"      Unlike paddles, they are not associated with sparks that may ignite fires.",
"     </li>",
"     <li>",
"      A rescuer is less likely to contact the patient's stretcher during shock delivery, as might occur with paddle use.",
"     </li>",
"     <li>",
"      Improper application of paddle pressure is eliminated as a possible reason for failure of defibrillation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Electrode size",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, one should use the largest paddles or electrode pads that will fit on the child&rsquo;s chest without touching. Paddles and electrode pads designed for adults are recommended for children who weigh more than 10 kg. Of these, those 12 cm in diameter seem to be superior to those that are 8 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/9\">",
"     9",
"    </a>",
"    ]. Infant paddles or pads are to be used for smaller infants weighing &lt;10 kg (",
"    <a class=\"graphic graphic_picture graphicRef60028 \" href=\"UTD.htm?8/3/8242\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Electrode placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     anterior/apex",
"    </span>",
"    position is most practical in the emergency setting and is typically used. The paddle or electrode pad held in the rescuer's left hand is placed to the right of the sternum below the clavicle [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/7\">",
"     7",
"    </a>",
"    ]. The paddle or electrode pad held in the rescuer's right hand is placed in the left midaxillary line, lateral to breast tissue, at the level of the nipple. If paddles are used, they must be applied with considerable, firm and steady pressure (",
"    <a class=\"graphic graphic_figure graphicRef59094 \" href=\"UTD.htm?1/40/1671\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Alternatively, an",
"    <span class=\"nowrap\">",
"     anterior/posterior",
"    </span>",
"    pad or paddle placement may be used with the anterior pad or paddle applied with the center of the paddle slightly to the left of the sternum and the posterior pad or paddle applied to the middle of the upper back (",
"    <a class=\"graphic graphic_figure graphicRef53963 \" href=\"UTD.htm?37/29/38356\">",
"     figure 5",
"    </a>",
"    ). This position may be preferred if adult electrodes must be used to deliver a countershock to an infant &lt;10 kilograms because infant paddles are unavailable. In this situation, the",
"    <span class=\"nowrap\">",
"     anterior/posterior",
"    </span>",
"    placement avoids the possibility of the large paddles contacting each other during shock delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Electrode-chest interface",
"    </span>",
"    &nbsp;&mdash;&nbsp;A flow of electrical current is needed for successful defibrillation. A high, transthoracic impedance will decrease the likelihood of success. When using paddles, concurrent use of conductive materials, such as electrode cream or paste will decrease transthoracic impedance.",
"   </p>",
"   <p>",
"    Paddles and electrode pads must not contact each other and care must be taken to avoid interface materials on one side of the chest contacting the material placed on the opposite side. Either of these conditions can result in arcing of the electrical current across the chest wall rather than conduction toward the heart.",
"   </p>",
"   <p>",
"    Interface materials to be avoided include saline, isopropyl alcohol, and ultrasound gel as well as the use of bare paddles. In addition to lower efficacy, isopropyl alcohol poses a risk of fire. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Rescuer and bystander safety'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Machine operation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should gain familiarity with the specific functions of the defibrillator in use in their health care setting. The following provides the typical steps involved in using a manual defibrillator:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apply electrode pads of the proper size or if paddles are used, a conductive material to the paddles.",
"     </li>",
"     <li>",
"      Turn on the manual defibrillator.",
"     </li>",
"     <li>",
"      If paddles are employed, use them to monitor the heart rhythm; this will avoid the need for separate EKG electrodes.",
"     </li>",
"     <li>",
"      Next, select asynchronous mode to defibrillate (eg, ventricular fibrillation, ventricular tachycardia without a pulse) or synchronous mode to cardiovert (eg, unstable supraventricular tachycardia, ventricular tachycardia with a pulse).",
"     </li>",
"     <li>",
"      Choose the energy dose:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Defibrillation dose",
"      </strong>",
"      &mdash; Doses of 2",
"      <span class=\"nowrap\">",
"       J/kg",
"      </span>",
"      for the first attempt, 4",
"      <span class=\"nowrap\">",
"       J/kg",
"      </span>",
"      for the second attempt, and 4",
"      <span class=\"nowrap\">",
"       J/kg",
"      </span>",
"      or higher (maximum dose 10",
"      <span class=\"nowrap\">",
"       J/kg,",
"      </span>",
"      or adult maximum [200 J, biphasic; 360 J monophasic]) for subsequent attempts are recommended for defibrillation of children with ventricular fibrillation (VF) or ventricular tachycardia without a pulse (pVT) (",
"      <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"       algorithm 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      However, the optimal energy dose for defibrillation in children has not been established. The currently recommended doses are based on a small study of just 27 children that was performed decades ago [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/13\">",
"       13",
"      </a>",
"      ]. In this series, termination of",
"      <span class=\"nowrap\">",
"       VF/pVT",
"      </span>",
"      occurred in 91 percent of 57 delivered shocks. Subsequent evidence suggests that currently recommended doses for children may not be as effective as previously thought [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. As an example, an observational study of 266 children with 285 in-hospital events warranting defibrillation found that an initial shock dose of 2",
"      <span class=\"nowrap\">",
"       J/kg",
"      </span>",
"      resulted in termination of",
"      <span class=\"nowrap\">",
"       VF/pVT",
"      </span>",
"      in only 55 percent of children and that increasing the initial dose was",
"      <strong>",
"       not",
"      </strong>",
"      associated with a greater likelihood of termination of",
"      <span class=\"nowrap\">",
"       VF/pVT",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/15\">",
"       15",
"      </a>",
"      ]. Furthermore, the 52 patients who received initial shock doses of 4",
"      <span class=\"nowrap\">",
"       J/kg",
"      </span>",
"      were less likely to have termination of",
"      <span class=\"nowrap\">",
"       VF/pVT",
"      </span>",
"      or to survive the event when compared to the 186 children who received 2",
"      <span class=\"nowrap\">",
"       J/kg",
"      </span>",
"      (adjusted OR 0.42 [95% CI 0.18-0.98] for termination of",
"      <span class=\"nowrap\">",
"       VF/pVT",
"      </span>",
"      and adjusted OR 0.41 [95% CI 0.21-0.81] for event survival). Thus, further study is necessary to identify optimal defibrillation doses in children. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Synchronized cardioversion dose",
"      </strong>",
"      &mdash; The dose for the first shock should be 0.5 to 1",
"      <span class=\"nowrap\">",
"       J/kg;",
"      </span>",
"      subsequent shocks are 2",
"      <span class=\"nowrap\">",
"       J/kg",
"      </span>",
"      (",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 3",
"      </a>",
"      ). Cardioversion is appropriate for unstable patients noted to have SVT, atrial fibrillation, atrial flutter, or VT with palpable pulses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deliver the current as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The electrode pads or paddles are placed in the",
"      <span class=\"nowrap\">",
"       anterior/apex",
"      </span>",
"      positions and the machine is charged. At the same time, oxygen sources and any flammable material should be at least 1 m away from the patient.",
"     </li>",
"     <li>",
"      Ensure all personnel are clear from the patient and the patient's stretcher by loudly stating \"All Clear!\" prior to shock delivery.",
"     </li>",
"     <li>",
"      Discharge the electrode pads or paddles. Both charging and energy release may be initiated by using buttons on the paddle, or if electrical pads are used, by utilizing a button on the machine itself or by using an attached foot pad.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Automated external defibrillator use in infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US Food and Drug Administration has approved AEDs for use in children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/13\">",
"     13",
"    </a>",
"    ]. The most recent AHA and international guidelines state that AEDs may be used for shock delivery in infants and children for treatment of out-of-hospital VF or pulseless VT. The order of preference for device is as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    (1) Manual defibrillator",
"   </p>",
"   <p>",
"    (2) AED with a dose attenuator device for children under eight years of age",
"   </p>",
"   <p>",
"    (3) AED without a dose attenuator",
"   </p>",
"   <p>",
"    Several recent advances in AED technology have allowed for their pediatric use. Studies show that AEDs are highly accurate in detecting abnormal rhythms in children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/13\">",
"     13",
"    </a>",
"    ]. They have demonstrated both high sensitivity in detecting VF and high specificity in identifying non-shockable rhythms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/19\">",
"     19",
"    </a>",
"    ]. A second advance is the development of attenuation devices, such as pads and cables which decrease the energy delivered to children.",
"   </p>",
"   <p>",
"    For in-hospital defibrillation, there are no data comparing manual defibrillators with AEDs in children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/7-9\">",
"     7-9",
"    </a>",
"    ], nor are there clear guidelines specifying the use of one over the other. The AHA does state that \"AEDs may be considered for the hospital setting as a way to facilitate early defibrillation (a goal of &le;3 minutes from collapse), especially in areas where staff have no rhythm recognition skills or defibrillators are used infrequently&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, for defibrillation of infants and children, institution-specific practices will prevail and a clinician may use either a manual defibrillator or an AED with a pediatric dose attenuation device.",
"   </p>",
"   <p>",
"    A large cohort study that evaluated the use of AEDs for hospitalized adults who suffered a sudden cardiac arrest found no survival benefit in adults with shockable rhythms and worse outcomes for adults without a shockable rhythm who were treated with an AED. Use of the automated external defibrillators (AED) in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=see_link&amp;anchor=H13#H13\">",
"     \"Automated external defibrillators\", section on 'In-hospital AED allocation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Automated external defibrillator operation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A principle reason for the growing prevalence of AEDs in society is their ease of use. The typical AED provides voice prompts for each step in its use after the machine is turned on:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apply adhesive electrode pads supplied with the machine. The electrode size and placement are the same as with manual defibrillators. As noted earlier, pediatric attenuated electrodes should be used in patients under eight years of age. The",
"      <span class=\"nowrap\">",
"       anterior/apex",
"      </span>",
"      position is recommended for pad placement although for younger children, the",
"      <span class=\"nowrap\">",
"       anterior/posterior",
"      </span>",
"      position may avoid the problem of the pads contacting each other.",
"     </li>",
"     <li>",
"      Plug pads into the AED.",
"     </li>",
"     <li>",
"      Stay clear of the patient while the machine is analyzing the cardiac rhythm.",
"     </li>",
"     <li>",
"      If a shock is indicated, the machine will charge and a voice prompt will instruct the rescuer to deliver a shock, which is accomplished by pressing a button.",
"     </li>",
"     <li>",
"      Resume CPR immediately after shock delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most AEDs in use today deliver between 150 to 360 J of energy, depending on the model. A standard AED without a dose attenuator is recommended for children older than eight years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/20\">",
"     20",
"    </a>",
"    ]. For those under eight years of age, an initial pediatric attenuated dose should be given. These attenuation devices will decrease the delivered dose to 35 to 50 J depending on the specific AED; some will allow higher doses for subsequent shocks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/21\">",
"     21",
"    </a>",
"    ]. Note that dosing is not weight-based. However, there appears to be a wide therapeutic range of energy doses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/22\">",
"     22",
"    </a>",
"    ]. The energy dose needed to produce histologic damage to myocardium is many times greater than that needed to defibrillate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, a standard AED without a dose attenuator is acceptable for infants and younger children, if it is the only device available [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inappropriate defibrillation of a patient with a perfusing, organized rhythm may cause ventricular fibrillation.",
"   </p>",
"   <p>",
"    Oxygen use represents an important fire hazard when electrical current is being delivered. A not infrequent scenario is for a patient in arrest to receive 100 percent oxygen via bag-valve-mask (BVM) ventilation. At the moment of shock delivery, the BVM apparatus may be placed such that oxygen is blowing across the patient's chest. This represents a significant fire hazard if a spark from a poorly placed paddle contacts the oxygen. All oxygen sources must be removed at least 1 m from the patient before defibrillation.",
"   </p>",
"   <p>",
"    Although uncommon, other potential dose-related complications include arrhythmias, myocardial injury, or skin burns [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21272/abstract/7\">",
"     7",
"    </a>",
"    ]. Risk of these problems is decreased by using lower energy doses and decreasing transthoracic impedance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following successful defibrillation or cardioversion, a child will need to be hospitalized for continuous cardiac monitoring in an intensive care setting. Depending on the etiology of the arrhythmia, consultation with a pediatric cardiologist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologist may also be appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Defibrillation (DF) and cardioversion are methods of delivering electrical energy to the heart through the chest wall in an attempt to restore the heart's normal rhythm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Defibrillation is the asynchronous delivery of energy, such as, the shock is delivered randomly during the cardiac cycle.",
"     </li>",
"     <li>",
"      Cardioversion is the delivery of energy that is synchronized to the QRS complex. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Defibrillation is indicated in the treatment of the following: ventricular fibrillation and pulseless ventricular tachycardia. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardioversion should be used in unstable patients with organized cardiac rhythms, such as supraventricular tachycardia (SVT), atrial fibrillation, atrial flutter, or ventricular tachycardia with a palpable pulse. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac rhythms that should not be treated with electrical current include sinus rhythm, stable SVT, asystole, pulseless electrical activity, and bradycardia. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Contraindications and precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk of electrical shock to a bystander or rescuer and fire are the two main safety issues related to the use of electrical countershock.",
"     </li>",
"     <li>",
"      The tables summarize the procedure for defibrillation (",
"      <a class=\"graphic graphic_table graphicRef50341 \" href=\"UTD.htm?10/12/10444\">",
"       table 1",
"      </a>",
"      ) and cardioversion (",
"      <a class=\"graphic graphic_table graphicRef74475 \" href=\"UTD.htm?17/41/18076\">",
"       table 2",
"      </a>",
"      ) and provide clinical tips for the use of a manual (",
"      <a class=\"graphic graphic_table graphicRef79418 \" href=\"UTD.htm?24/41/25244\">",
"       table 3",
"      </a>",
"      ) or automated (",
"      <a class=\"graphic graphic_table graphicRef74523 \" href=\"UTD.htm?33/7/33915\">",
"       table 4",
"      </a>",
"      ) defibrillator. The algorithms indicate recommended rhythms, dosing, and adjunct treatments for the use of defibrillation and cardioversion in children (",
"      <a class=\"graphic graphic_algorithm graphicRef80003 \" href=\"UTD.htm?41/30/42470\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/1\">",
"      Young KD, Gausche-Hill M, McClung CD, Lewis RJ. A prospective, population-based study of the epidemiology and outcome of out-of-hospital pediatric cardiopulmonary arrest. Pediatrics 2004; 114:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/2\">",
"      Young KD, Seidel JS. Pediatric cardiopulmonary resuscitation: a collective review. Ann Emerg Med 1999; 33:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/3\">",
"      Martin DR, Gavin T, Bianco J, et al. Initial countershock in the treatment of asystole. Resuscitation 1993; 26:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/4\">",
"      Smith BT, Rea TD, Eisenberg MS. Ventricular fibrillation in pediatric cardiac arrest. Acad Emerg Med 2006; 13:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/5\">",
"      Mogayzel C, Quan L, Graves JR, et al. Out-of-hospital ventricular fibrillation in children and adolescents: causes and outcomes. Ann Emerg Med 1995; 25:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/6\">",
"      Khoury A, Shavit I. Out-of-hospital ventricular fibrillation in three adolescents. Arch Dis Child 2009; 94:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/7\">",
"      Deakin CD, Nolan JP, European Resuscitation Council. European Resuscitation Council guidelines for resuscitation 2005. Section 3. Electrical therapies: automated external defibrillators, defibrillation, cardioversion and pacing. Resuscitation 2005; 67 Suppl 1:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/8\">",
"      American Heart Association. Part 3: Defibrillation. Circulation 2005; 112:III-17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/9\">",
"      Link MS, Atkins DL, Passman RS, et al. Part 6: electrical therapies: automated external defibrillators, defibrillation, cardioversion, and pacing: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/10\">",
"      Hazinski MF, Nadkarni VM, Hickey RW, et al. Major changes in the 2005 AHA Guidelines for CPR and ECC: reaching the tipping point for change. Circulation 2005; 112:IV206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/11\">",
"      Hoke RS, Heinroth K, Trappe HJ, Werdan K. Is external defibrillation an electric threat for bystanders? Resuscitation 2009; 80:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/12\">",
"      American Heart Association. Part 12: Pediatric advanced life support. Circulation 2005; 112:IV-167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/13\">",
"      Markenson D, Pyles L, Neish S, et al. Ventricular fibrillation and the use of automated external defibrillators on children. Pediatrics 2007; 120:e1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/14\">",
"      Rossano JW, Quan L, Kenney MA, et al. Energy doses for treatment of out-of-hospital pediatric ventricular fibrillation. Resuscitation 2006; 70:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/15\">",
"      Meaney PA, Nadkarni VM, Atkins DL, et al. Effect of defibrillation energy dose during in-hospital pediatric cardiac arrest. Pediatrics 2011; 127:e16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/16\">",
"      Berg MD, Schexnayder SM, Chameides L, et al. Pediatric basic life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Pediatrics 2010; 126:e1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/17\">",
"      Berg MD, Schexnayder SM, Chameides L, et al. Part 13: pediatric basic life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/18\">",
"      Kleinman ME, de Caen AR, Chameides L, et al. Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Pediatrics 2010; 126:e1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/19\">",
"      Atkins DL, Kenney MA. Automated external defibrillators: safety and efficacy in children and adolescents. Pediatr Clin North Am 2004; 51:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/20\">",
"      International Liaison Committee on Resuscitation (ILCOR). Part 6: Pediatric basic and advanced life support. Circulation 2005; 112:III-73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/21\">",
"      Samson RA, Atkins DL. Tachyarrhythmias and defibrillation. Pediatr Clin North Am 2008; 55:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21272/abstract/22\">",
"      American Academy of Pediatrics Committee on Pediatric Emergency Medicine, American Academy of Pediatrics Section on Cardiology and Cardiac Surgery, Markenson D. Ventricular fibrillation and the use of automated external defibrillators on children. Pediatrics 2007; 120:1159.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6311 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_49_21272=[""].join("\n");
var outline_f20_49_21272=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Defibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cardioversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ANATOMY AND PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cardioversion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Defibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Shock delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Coordination of shock delivery and chest compressions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CONTRAINDICATIONS AND PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Rescuer and bystander safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Patient counseling/informed consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Analgesia and sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Methods: Manual defibrillator use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Electrode choice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Electrode size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Electrode placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Electrode-chest interface",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Machine operation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Automated external defibrillator use in infants and children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Automated external defibrillator operation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6311\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6311|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?41/30/42470\" title=\"algorithm 1\">",
"      Pediatric cardiac arrest algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?17/38/18018\" title=\"algorithm 2\">",
"      Pediatric basic life support algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/37/11860\" title=\"algorithm 3\">",
"      Pediatric tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6311|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/63/35827\" title=\"figure 1\">",
"      Conduction system action potentials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/61/2006\" title=\"figure 2\">",
"      Major deflections on ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/43/44726\" title=\"figure 3\">",
"      Cardiac cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/40/1671\" title=\"figure 4\">",
"      Anterior-apex paddle position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/29/38356\" title=\"figure 5\">",
"      Anteroposterior paddle position",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6311|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/3/8242\" title=\"picture 1\">",
"      Paddle size",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6311|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/12/10444\" title=\"table 1\">",
"      Clinical summary manual defibrillation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/41/18076\" title=\"table 2\">",
"      Clinical summary cardioversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/41/25244\" title=\"table 3\">",
"      Defibrillation cardioversion tips",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/7/33915\" title=\"table 4\">",
"      Automatic external defibrillator use in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6311|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?32/61/33757\" title=\"waveform 1\">",
"      Defibrillation waveforms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=related_link\">",
"      Automated external defibrillators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7864?source=related_link\">",
"      Basic life support in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=related_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=related_link\">",
"      Management of supraventricular tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/62/42984?source=related_link\">",
"      Reentry and the development of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_49_21273="Pulmonary infections in immunocompromised patients";
var content_f20_49_21273=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary infections in immunocompromised patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/49/21273/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/49/21273/contributors\">",
"     Jay A Fishman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/49/21273/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/49/21273/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/49/21273/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/49/21273/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/49/21273/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of potential pathogens known to cause pulmonary infections in immunocompromised individuals has grown as a result of intensified immunosuppression, prolonged patient survival, the emergence of antimicrobial-resistant pathogens, and improved diagnostic assays. Immunocompromised hosts are defined by susceptibility to infection with organisms of little native virulence in normal individuals. Each group of hosts (eg, AIDS, solid organ transplant recipients, or hematopoietic cell transplant recipients) has enhanced susceptibility to a subset of pathogens depending upon the nature of the underlying immune defects. The impact of antibody-based therapies against T and B lymphocytes and tumor necrosis factor-alpha should be considered in the assessment of risk.",
"   </p>",
"   <p>",
"    Survival has improved with the availability of newer antimicrobial agents, including azole antifungals, macrolides, antivirals, and antiretroviral drugs. Despite these advances, pulmonary infection remains the most common form of documented tissue invasive infection observed in these hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common pulmonary infections in the immunocompromised host will be reviewed here. The risk of pneumonia and approaches to the evaluation and diagnosis of pulmonary infiltrates in the immunocompromised individual and the treatment of specific disease entities are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infectious risks associated with specific immunomodulating agents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link\">",
"     \"Secondary immune deficiency induced by drugs and biologics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of general considerations apply in the immunocompromised patient with a pulmonary infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple simultaneous infectious processes are common. These may include dual infection with Pneumocystis jirovecii (formerly P. carinii) and cytomegalovirus, or superimposition of another process (lung injury or drug toxicity). Sequential infection (eg, viral infection preceding bacterial or fungal infection) is also common.",
"     </li>",
"     <li>",
"      Early imaging (computed tomography [CT] scan) and specific microbiologic diagnoses are essential to the care of immunocompromised patients. Invasive procedures (biopsies and bronchoscopy) are often necessary to establish a microbiologic diagnosis. Antimicrobial susceptibility testing and advanced diagnostic testing including immunohistology and quantitative molecular assays are essential components of the management of pneumonia in immunocompromised patients. The importance of specific microbiologic diagnoses in the care of immunocompromised individuals cannot be over-emphasized.",
"     </li>",
"     <li>",
"      Microbicidal therapy must be started as soon as possible. Empiric therapy should be based upon the data that are available (epidemiologic history, sputum Gram stain, special stains, prior microbiologic data, previous courses of antimicrobial agents). Overly broad antimicrobial therapy can be modified based upon new microbiologic data.",
"     </li>",
"     <li>",
"      Reduction of the overall level of immune suppression may be as important as antimicrobial therapy in the ultimate success of treatment.",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Host susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of a specific pathogen is influenced by the patient's underlying innate and adaptive immune defects. In practice, most patients have mixed immune defects.",
"   </p>",
"   <p>",
"    The encapsulated bacteria as a group are of greatest concern in patients with underlying or induced humoral immune deficiencies with accompanying diminished opsonizing capacity. Severe pneumonia secondary to Streptococcus pneumoniae is described in patients with functional asplenia, hematopoietic malignancy, transplantation, or immunoglobulin deficiency. In addition, immune deficiency prevents the development of complete, protective immunity after pneumococcal immunization, although infection seems less severe in vaccinated, compromised individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of intracellular organisms (eg, Mycobacteria, Legionella, Nocardia, Strongyloides) and infection due to yeasts (eg, Histoplasma, Cryptococcus) or molds (eg, Aspergillus) reflect decreased cell-mediated immunity or macrophage function. Such infections have become prominent in patients receiving T-lymphocyte depleting therapies for rheumatologic diseases or inflammatory bowel disease. Nocardia and staphylococcal infections are more common in patients with neutrophil dysfunction (chronic granulomatous disease) or neutropenia, but may also occur in patients receiving glucocorticoids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T-cell suppression. As an example, organ transplant recipients who require long-term immune suppression are at greater risk for unusual infections (eg, Nocardia, nontuberculous mycobacteria) than immunocompetent adults.",
"   </p>",
"   <p>",
"    The immunocompromised patient is also more likely to present with disseminated disease, including involvement of the central nervous system (eg, Aspergillus species, mycobacterial, or Nocardia infections). When disseminated disease is being considered, MRI of the CNS, sampling of the cerebrospinal fluid, and bone imaging (eg, bone scan) are helpful in the detection of metastatic infection and the assessment of the efficacy of therapy (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=see_link\">",
"     \"Clinical manifestations and diagnosis of nocardiosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=see_link\">",
"     \"Central nervous system tuberculosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATTERNS OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient exposures and the nature of the host immune defects influence the pattern of pulmonary infection. These infections can be divided into the following general categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Community-acquired",
"     </li>",
"     <li>",
"      Nosocomial",
"     </li>",
"     <li>",
"      Reactivation",
"     </li>",
"     <li>",
"      Environmental exposure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Community-acquired infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial pneumonia in the immunocompromised host most often involves the same pathogens acquired in the community by immunocompetent hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/8\">",
"     8",
"    </a>",
"    ]. However, pneumonia in the immunocompromised patient in the community often follows an infection caused by respiratory viruses, atypical pathogens, or cytomegalovirus (CMV) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/2\">",
"     2",
"    </a>",
"    ]. These postviral infections are of greater severity with rapid onset of progression and high morbidity. Knowledge of the local epidemiology of infection (eg, prevalence of metapneumovirus or influenza A in the community) may guide the approach to diagnosis and therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential for antimicrobial resistance in the compromised host population exceeds that in the general population, in part because of exposures to the hospital environment and to antimicrobial agents for treatment and prophylaxis, and frequently, ongoing microbial replication [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Inadequate initial (empiric) therapy of pneumonia has been linked to increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hospital-acquired (nosocomial) or healthcare-associated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematogenous seeding of the lungs in association with bacteremia or fungemia is common in neutropenic hosts, often in association with vascular access catheters, skin, or gastrointestinal lesions. Hospital-acquired (nosocomial) or healthcare-associated infections arise in patients with preexisting lung injury (COPD, bronchiectasis), during intubation, or following aspiration. This is a particular problem in patients who are debilitated, have hepatic or renal dysfunction, encephalopathy, or are otherwise unable to protect their airways.",
"   </p>",
"   <p>",
"    Such pneumonias usually involve relatively resistant gram-negative bacilli or fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/11\">",
"     11",
"    </a>",
"    ]. For example, Klebsiella pneumoniae, Stenotrophomonas maltophilia, and Burkholderia cepacia are particularly resistant organisms that can colonize skin, catheters, endotracheal tubes, wound hematomas, and tracheal anastomoses. Patients with cystic fibrosis and lung and liver transplant recipients are especially vulnerable to infection with these organisms. Once these organisms cause a pulmonary infection, a combination of ablative surgery and bactericidal antimicrobial agents may be required for cure. Streptococci, including those resistant to fluoroquinolones used for prophylaxis, have also been implicated in pneumonia in these hosts.",
"   </p>",
"   <p>",
"    Lung transplant patients have a higher risk of developing pulmonary infection than other transplant recipients. This occurs for several reasons including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extended intubation and colonization of the lower respiratory tract",
"     </li>",
"     <li>",
"      Surgical trauma of the transplanted lung (suture line infection, disruption of lymphatic drainage, diminished vascular supply)",
"     </li>",
"     <li>",
"      Mechanical factors (diminished ciliary function and cough reflex)",
"     </li>",
"     <li>",
"      Immunosuppression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infections in lung transplant recipients are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link\">",
"     \"Fungal infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=see_link\">",
"     \"Tuberculosis in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=see_link\">",
"     \"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Environmental exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major sources of environmental pathogens that lead to pulmonary infection in immunocompromised hosts are air, soil, and potable water.",
"   </p>",
"   <p>",
"    Epidemic gram-negative pneumonia (due to organisms such as Legionella pneumophila and Pseudomonas aeruginosa) occurs in patients due to a contaminated water or air supply. Nontuberculous mycobacteria are also commonly found in water supplies. Exposure to soil has been linked to infections with Aspergillus and Nocardia spp, or to Penicillium marneffei and Burkholderia pseudomallei in Southeast Asia. Burkholderia cepacia strains from soil have been demonstrated to match clinical isolates in cystic fibrosis patients using genotyping techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32680?source=see_link\">",
"     \"Epidemiology and pathogenesis of Legionella infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27145?source=see_link\">",
"     \"Epidemiology and pathogenesis of Pseudomonas aeruginosa infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33302?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Penicillium marneffei infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23991?source=see_link\">",
"     \"Microbiology, epidemiology, and pathogenesis of nocardiosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link&amp;anchor=H1627022308#H1627022308\">",
"     \"Bacterial infections following lung transplantation\", section on 'Burkholderia cepacia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unique epidemiologic risks (travel, gardening) must be considered. Travel history is important in considering the risk of certain endemic fungi (Histoplasma, Coccidioides, Blastomyces) as opposed to the ubiquitous fungi (Aspergillus, Cryptococcus neoformans).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Reactivation infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompromised patients can reactivate many latent infections, including cytomegalovirus, strongyloidiasis, cryptococcosis, toxoplasmosis, or mycobacterial infection, long after the initial exposure as a result of immune defects.",
"   </p>",
"   <p>",
"    Serologic testing for Strongyloides or Toxoplasma will generally demonstrate IgG antibodies consistent with prior exposure. Once exposed, IgG antibodies remain detectable for life.",
"   </p>",
"   <p>",
"    Knowledge of tuberculin skin testing (TST) prior to the development of immune compromise is helpful. If TST skin testing is performed, a 5 mm response is considered positive in most intensively immunocompromised patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\", section on 'Interpreting the TST'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=see_link\">",
"     \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=see_link\">",
"     \"Tuberculosis in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although nontuberculous mycobacterial (NTM) infection rates are low compared with other types of infection, when NTM infections occur in transplant recipients they cause significant morbidity and mortality. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=see_link\">",
"     \"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of pulmonary infections in the immunocompromised host is broad, and includes bacteria, fungi, viruses, and parasites. The following discussion addresses the most common pathogens that should be considered in the differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-acquired pathogens include S. pneumoniae, H. influenzae, Mycoplasma, Legionella, Chlamydia, and others. Increasing resistance of pneumococci to penicillin and other antimicrobials is notable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective review of patients diagnosed with tuberculosis at Memorial Sloan-Kettering Cancer Center, patients with hematologic neoplasms and head and neck cancer had rates of tuberculosis 40 and 20 times greater than the rate among the United States population, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/13\">",
"     13",
"    </a>",
"    ]. Thus, tuberculosis must be considered in these patients with pulmonary infiltrates.",
"   </p>",
"   <p>",
"    The nature and time course of immunosuppression is also an important factor to consider. Neutropenic patients who develop immunosuppression more acutely can develop infection due to invasive nosocomial or colonizing organisms (eg, Pseudomonas, Aspergillus). Successful empiric therapy generally includes agents active against organisms previously identified in the individual. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fungi",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three most important causes of fungal pulmonary infection are Pneumocystis jirovecii (previously known as P. carinii), Aspergillus species (especially A. fumigatus), and Cryptococcus neoformans [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/2,14-22\">",
"     2,14-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pneumocystis jirovecii",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of Pneumocystis jirovecii (formerly P. carinii) pneumonia is greatest in the first six months after transplantation and during periods of intensified immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/14-17,23\">",
"     14-17,23",
"    </a>",
"    ]. The natural reservoir of infection remains unknown. Aerosol transmission of infection has been demonstrated by a number of investigators in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Clusters of infections have been documented in HIV-infected patients, renal transplant recipients, and patients with hematologic malignancies; one genotyping study showed that person-to-person transmission could occur in these settings but is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/26\">",
"     26",
"    </a>",
"    ]. Both new exposures and reactivation of undertreated prior infections remain significant factors in the incidence of disease in immunocompromised hosts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=see_link\">",
"     \"Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients not receiving prophylaxis, the occurrence of Pneumocystis infection is highly associated with CMV infection, possibly because of the inhibitory effect of CMV on alveolar macrophages and T-lymphocyte function. Risk of infection is strongly associated with immune suppression that includes chronic glucocorticoid administration or T-lymphocyte depletion; bolus glucocorticoids and calcineurin inhibitor use may also contribute to risk of infection and increased mortality. Prophylaxis against Pneumocystis should be administered unless there are contraindications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=see_link\">",
"     \"Prophylaxis against Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hallmark of infection due to P. jirovecii is the presence of marked hypoxemia, dyspnea, and cough with a paucity of physical or radiologic findings. In transplant recipients, PCP is generally an acute or subacute infection. In lung transplant recipients, the rate of asymptomatic isolation of P. jirovecii approaches two-thirds of the total in some series. Of these, up to one-half are expected to develop symptomatic disease without treatment. For other immunocompromised patients without HIV infection, 5 to 12 percent of patients who are not receiving prophylaxis will develop pneumocystosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/15\">",
"     15",
"    </a>",
"    ]. In patients with HIV, PCP is a more rapidly progressive process with a greater organism burden than in non-HIV-infected immunocompromised hosts. The risk of PCP has declined in patients with HIV infection since the advent of highly active antiretroviral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Aspergillus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive pulmonary aspergillosis may present as a primary infection acquired from a nosocomial or environmental source, or occur due to failure to clear organisms that are already present in airways that are damaged by surgery or underlying disease. Infection due to non-fumigatus strains of Aspergillus and other molds may result in similar clinical presentations, hence specific microbial diagnosis is essential for guiding therapy.",
"   </p>",
"   <p>",
"    The risk of invasive pulmonary aspergillosis appears to be high once the respiratory tract, sinuses, or trachea are colonized and immunosuppression is maintained. \"Preemptive\" antifungal therapy may be indicated when colonization is noted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical course is determined by the pathologic features of this infection; a necrotizing bronchopneumonia with vascular invasion is common, with hemorrhage and extrapulmonary invasion occurring in some patients, particularly those who are neutropenic. Some patients already have extrapulmonary disease at the time of diagnosis; the brain and skin are the most common sites involved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Cryptococcus species",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcal infection is usually appreciated when an asymptomatic pulmonary nodule or lymph node enlargement appears on a routine chest radiograph. Occasionally, subacute consolidation with influenza-like symptoms may be noted. However, in one retrospective review, clinical symptoms were present in 74 percent of 38 patients with pulmonary cryptococcosis, the majority of whom were solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/27\">",
"     27",
"    </a>",
"    ]. The most frequent symptoms were shortness of breath, cough, and fever. The presence of a pleural effusion was a poor prognostic factor by multivariate regression analysis, and overall mortality was 24 percent. Our own clinical experience suggests that asymptomatic infection remains common [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major importance of cryptococcal pulmonary infection is that the lung is the portal of entry for disseminated infection, which frequently involves the central nervous system. Thus, an aggressive diagnostic evaluation must be initiated even for asymptomatic infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=see_link\">",
"     \"Cryptococcal infection outside the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Candida species",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although Candida species are frequently isolated from sputum, cases of pulmonary invasion are extremely rare even in immunocompromised hosts. Thus, a positive sputum culture for Candida albicans should not lead to specific therapy against Candida spp; other processes should be sought to explain pulmonary symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18055?source=see_link&amp;anchor=H4#H4\">",
"     \"Candida infections of the abdomen and thorax\", section on 'Pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By contrast, hematogenous seeding of the lungs during fungemia can occur with Candida species. Fungemia commonly results from infection of indwelling vascular access catheters and infection related to transplant surgery (particularly of the pancreas or liver). Other Candida species (eg, Candida glabrata and Candida krusei) have become more frequent pathogens in these hosts, possibly as a result of nosocomial exposures and prior exposure to prophylactic agents including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Susceptibility patterns'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'C. glabrata and C. krusei'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Agents of mucormycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The agents of mucormycosis, including Rhizopus, Mucor, and Absidia spp, cause invasive disease often involving the orbit and palate especially in diabetic patients. Diabetics, patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    therapy, or those with prolonged neutropenia or chronic sinus infections are at increased risk for these infections. These species cause rapidly expanding, often solitary, pulmonary lesions. Pneumonia is hemorrhagic with infarction; metastatic spread to the skin is common. Surgical excision is generally required in addition to antifungal therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"     \"Mucormycosis (zygomycosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other fungi",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of fungal pathogens in immunocompromised patients can also include atypical fungi with distinct antifungal susceptibility patterns. These include Scedosporium apiospermum (Pseudallescheria boydii) and Scedosporium prolificans, , Drechslera, Fusarium spp, Trichosporon spp, and Geotrichum candidum. Failure to respond to therapy may suggest these unusual fungal pathogens for which susceptibility testing may be required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36249?source=see_link\">",
"     \"Diagnosis and treatment of Scedosporium infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29018?source=see_link\">",
"     \"Antifungal susceptibility testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dematiaceous molds, such as",
"    <strong>",
"    </strong>",
"    Aureobasidium, Alternaria, Curvularia, Phialophora, Wangiella, Cladosporium are increasingly implicated as causes of sinus, pulmonary, and central nervous system disease in transplant and leukemic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/29\">",
"     29",
"    </a>",
"    ]. These filamentous organisms pose special therapeutic problems because they are often resistant to a number of antifungal agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) is the most common virus of concern in immunocompromised patients, especially transplant recipients. However, other viruses such as influenza, parainfluenza, and respiratory syncytial virus are diagnosed with greater frequency based upon the availability of rapid antigen testing.",
"   </p>",
"   <p>",
"    Most pulmonary viral infections in immunocompromised patients begin insidiously with constitutional symptoms including fever and a dry, nonproductive cough; some patients develop varying degrees of tachypnea, dyspnea, and hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Cytomegalovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV pneumonitis usually occurs one to four months posttransplant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/2,30\">",
"     2,30",
"    </a>",
"    ]. The attack rate and severity of pneumonia is greater in recipients of lung allografts than in the other transplant groups. The overall likelihood of developing CMV illness (infection or disease) in lung transplant recipients is approximately 50 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Solid organ recipients at greatest risk for primary CMV infection are donor seropositive and recipient seronegative. In contrast, the greatest risk for CMV pneumonitis following hematopoietic cell transplantation (HCT) occurs in the seropositive recipient of seronegative stem cells. The incidence of CMV is related to the intensity of the immunosuppressive therapy. CMV infections have increased in the face of T lymphocyte depleting therapies used in all forms of organ and stem cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/31\">",
"     31",
"    </a>",
"    ]. Much of the lung injury in the HCT recipient is due to immune responses to CMV antigens. Thus, a pneumonitis syndrome may not occur until after the reemergence of immune function with hematopoietic engraftment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link&amp;anchor=H193827185#H193827185\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\", section on 'Pulmonary infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The radiographic manifestations of CMV pneumonia can take many forms, but a bilateral, symmetrical, peribronchovascular, and alveolar process predominantly affecting the lower lobes is the most frequent. Less commonly, a focal consolidation more suggestive of a bacterial or fungal infection or even a solitary pulmonary nodule may be caused by CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/2\">",
"     2",
"    </a>",
"    ]. Mixed patterns on chest radiography should suggest dual infection; CMV and PCP or Aspergillus are common infections that may coexist in these hosts.",
"   </p>",
"   <p>",
"    CMV infection in transplant recipients is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Community-acquired respiratory viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunocompromised patient is also at increased risk for pneumonia with community-acquired respiratory viruses compared with normal hosts. Influenza, parainfluenza, RSV, and adenovirus infections are of special importance. Human metapneumovirus is an increasingly-recognized pathogen of immunocompromised children and adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=see_link\">",
"     \"Clinical manifestations of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=see_link\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/617?source=see_link\">",
"     \"Parainfluenza viruses in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=see_link\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=see_link\">",
"     \"Human metapneumovirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical history is key in determining the possibility of bacterial or other superinfection. Marked hypoxemia or purulence of sputum may suggest coinfection. Data from retrospective studies allow some generalizations about respiratory viral infections in transplant recipients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The seasonal variability of each respiratory virus in immunocompromised hosts reflects that seen in the general community. As a result, influenza, respiratory syncytial virus (RSV), and human metapneumovirus (hMPV) generally cause disease from November through April in the northern hemisphere; rhinovirus typically circulates in the fall and spring; and adenovirus and parainfluenza (PIV) circulate throughout the year [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/32\">",
"       32",
"      </a>",
"      ]. Some cases may be observed earlier in immunocompromised hosts than in the general community as harbingers of an impending outbreak.",
"     </li>",
"     <li>",
"      Respiratory viruses cause more severe disease with more frequent complications in immunocompromised individuals. The risk and severity of disease is greater in individuals with significant T cell defects. The true incidence of asymptomatic respiratory viral infection is unknown. Atypical presentations are common, and may go unrecognized. Progression to lower tract disease occurs in seven to fifty percent of hematopoietic cell transplant recipients and approximately 13 percent of solid organ transplant recipients infected with influenza [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/33\">",
"       33",
"      </a>",
"      ]. Lower tract disease may occur in the presence of negative screening assays for respiratory viruses (eg, nasal swabs for antigen detection). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=see_link\">",
"       \"Clinical manifestations of seasonal influenza in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=see_link\">",
"       \"Human metapneumovirus infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/38/617?source=see_link&amp;anchor=H12#H12\">",
"       \"Parainfluenza viruses in adults\", section on 'Immunocompromised hosts'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H413855640\">",
"    <span class=\"h3\">",
"     SARS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to community-acquired respiratory viruses, severe acute respiratory syndrome (SARS) has also been associated with a greater likelihood of progression to invasive disease and death in immunocompromised patients. Higher rates of morbidity can be due to higher levels of viremia and persistent replication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17753?source=see_link\">",
"     \"Severe acute respiratory syndrome (SARS)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Herpes simplex and varicella zoster viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with cutaneous herpes simplex (HSV) and varicella zoster (VZV) virus infections, viral dissemination to liver, lungs, brain, or gastrointestinal tract can occur in 10 percent of patients. Nasal, oropharyngeal, or esophageal HSV or VZV infections may spread directly to the lungs with the development of vesicular lesions in the trachea.",
"   </p>",
"   <p>",
"    Primary varicella pneumonia may accompany chickenpox in normal adults and in the immunocompromised host [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/34\">",
"     34",
"    </a>",
"    ]. Pulmonary involvement occurs within the first seven days of illness with mortality approaching 18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Chest radiographs will reveal nodular or interstitial infiltrates in up to 16 percent of adults with chickenpox, while only 10 to 25 of these will have clinical symptoms. Pulmonary involvement with HSV and VZV in the immunocompromised host should be considered a life-threatening emergency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Parasites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parasitic pathogens are not a common cause of pulmonary involvement in immunocompromised hosts. However, infection with Strongyloides stercoralis and Toxoplasma gondii are important diagnostic considerations since they can lead to life-threatening infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Strongyloides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperinfection strongyloidiasis is generally associated with conditions of depressed host cellular immunity. Autoinfection within the gastrointestinal tract begins when rhabditiform larvae transform into filariform larvae, which penetrate the intestinal wall to enter the bloodstream. The massive dissemination of filariform larvae to the lungs, liver, heart, central nervous system, and endocrine glands induces inflammation that may result in symptomatic dysfunction of these organs. The chest radiograph reveals pulmonary infiltrates that consist of foci of hemorrhage, pneumonitis, and edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=see_link\">",
"     \"Strongyloidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rapid reproduction occurs in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients receiving glucocorticoids and calcineurin inhibitors",
"     </li>",
"     <li>",
"      Solid organ and hematopoietic transplant recipients",
"     </li>",
"     <li>",
"      Burn victims",
"     </li>",
"     <li>",
"      Alcoholics",
"     </li>",
"     <li>",
"      Individuals with hypogammaglobulinemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Toxoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasma gondii pneumonia is uncommon, but when it occurs, usually represents reactivation of latent infection. Thus, patients at risk are typically seropositive for this pathogen (40 percent of adults in the United States and 70 percent in Europe, South America, and Africa). Over 95 percent of clinical disease is restricted to the central nervous system, but T. gondii can cause chorioretinitis and pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Heart and lung transplant recipients who are seronegative and receive an organ from a seropositive donor appear to be a high-risk group for T. gondii infection with an incidence approaching 80 percent without prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21273/abstract/14\">",
"     14",
"    </a>",
"    ]. Most infections affect only the transplanted organ, but some of these cases are disseminated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53648202\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The spectrum of potential pathogens known to cause pulmonary infections in immunocompromised individuals has grown as a result of intensified immunosuppression, prolonged patient survival, the emergence of antimicrobial-resistant pathogens, and improved diagnostic assays. Immunocompromised hosts are defined by susceptibility to infection with organisms of little native virulence in normal individuals. Each group of hosts (eg, AIDS, solid organ transplantation, or hematopoietic cell transplantation) has enhanced susceptibility to a subset of pathogens depending upon the nature of the underlying immune defects. The risk for severe pulmonary infection should be considered a reflection of the intensity, persistence, and nature of immune deficiencies. The impact of antibody-based therapies against T and B lymphocytes and tumor necrosis factor-alpha should be considered in the assessment of risk. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of general considerations apply in the immunocompromised patient with a pulmonary infection:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Multiple simultaneous infectious processes are common. These may include dual infection with Pneumocystis jirovecii (formerly P. carinii) and cytomegalovirus, or superimposition of another process (lung injury or drug toxicity). Sequential infection (eg, viral infection preceding bacterial or fungal infection) is also common.",
"     </li>",
"     <li>",
"      Early imaging (computed tomography [CT] scan) and specific microbiologic diagnoses are essential to the care of these patients. Invasive procedures (biopsies and bronchoscopy) are often necessary to establish a microbiologic diagnosis. Antimicrobial susceptibility testing and advanced diagnostic testing including immunohistology and quantitative molecular assays are essential components of the management of pneumonia in immunocompromised patients.",
"     </li>",
"     <li>",
"      Microbicidal therapy must be started as soon as possible. Empiric therapy should be based upon the data that are available (epidemiologic history, sputum Gram stain, special stains, prior microbiologic data, previous courses of antimicrobial agents). Overly broad antimicrobial therapy can be modified based upon more specific microbiologic data.",
"     </li>",
"     <li>",
"      Reduction of the overall level of immune suppression may be as important as antimicrobial therapy in the ultimate success of treatment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General considerations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient exposures and the nature of the host immune defects influence the pattern of pulmonary infection. These infections can be divided into the following general categories:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Community-acquired (common pathogens)",
"     </li>",
"     <li>",
"      Hospital-acquired (nosocomial) or healthcare-associated",
"     </li>",
"     <li>",
"      Reactivation (latent infections)",
"     </li>",
"     <li>",
"      Environmental exposures (patient-specific exposures) (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patterns of infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis of pulmonary infections in the immunocompromised host is broad, and includes bacteria, fungi, viruses, and parasites. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pathogens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/1\">",
"      Ettinger NA, Trulock EP. Pulmonary considerations of organ transplantation. Part I. Am Rev Respir Dis 1991; 143:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/2\">",
"      Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/3\">",
"      Ramsey PG, Rubin RH, Tolkoff-Rubin NE, et al. The renal transplant patient with fever and pulmonary infiltrates: etiology, clinical manifestations, and management. Medicine (Baltimore) 1980; 59:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/4\">",
"      Rosenow EC 3rd. Diffuse pulmonary infiltrates in the immunocompromised host. Clin Chest Med 1990; 11:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/5\">",
"      Winston DJ, Emmanouilides C, Busuttil RW. Infections in liver transplant recipients. Clin Infect Dis 1995; 21:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/6\">",
"      Kumar D, Rotstein C, Miyata G, et al. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003; 187:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/7\">",
"      Blumberg EA, Brozena SC, Stutman P, et al. Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin Infect Dis 2001; 32:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/8\">",
"      Camps Serra M, Cervera C, Pumarola T, et al. Virological diagnosis in community-acquired pneumonia in immunocompromised patients. Eur Respir J 2008; 31:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/9\">",
"      de Bruyn G, Whelan TP, Mulligan MS, et al. Invasive pneumococcal infections in adult lung transplant recipients. Am J Transplant 2004; 4:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/10\">",
"      Fern&aacute;ndez Guerrero ML, Ramos JM, Marrero J, et al. Bacteremic pneumococcal infections in immunocompromised patients without AIDS: the impact of beta-lactam resistance on mortality. Int J Infect Dis 2003; 7:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/11\">",
"      Gastmeier P, Groneberg K, Weist K, R&uuml;den H. A cluster of nosocomial Klebsiella pneumoniae bloodstream infections in a neonatal intensive care department: Identification of transmission and intervention. Am J Infect Control 2003; 31:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/12\">",
"      LiPuma JJ, Spilker T, Coenye T, Gonzalez CF. An epidemic Burkholderia cepacia complex strain identified in soil. Lancet 2002; 359:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/13\">",
"      Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis 2006; 42:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/14\">",
"      Fishman JA. Pneumocystis carinii and parasitic infections in transplantation. Infect Dis Clin North Am 1995; 9:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/15\">",
"      Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/16\">",
"      Fishman JA. Treatment of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/17\">",
"      Fishman JA, Roth RS, Zanzot E, et al. Use of induced sputum specimens for microbiologic diagnosis of infections due to organisms other than Pneumocystis carinii. J Clin Microbiol 1994; 32:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/18\">",
"      George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/19\">",
"      Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 1995; 9:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/20\">",
"      Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/21\">",
"      Hadley S, Samore MH, Lewis WD, et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/22\">",
"      Weiland D, Ferguson RM, Peterson PK, et al. Aspergillosis in 25 renal transplant patients. Epidemiology, clinical presentation, diagnosis, and management. Ann Surg 1983; 198:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/23\">",
"      Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/24\">",
"      Dei-Cas E, Brun-Pascaud M, Bille-Hansen V, et al. Animal models of pneumocystosis. FEMS Immunol Med Microbiol 1998; 22:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/25\">",
"      Wakefield AE, Stringer JR, Tamburrini E, Dei-Cas E. Genetics, metabolism and host specificity of Pneumocystis carinii. Med Mycol 1998; 36 Suppl 1:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/26\">",
"      Helweg-Larsen J, Tsolaki AG, Miller RF, et al. Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. QJM 1998; 91:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/27\">",
"      Vilchez RA, Irish W, Lacomis J, et al. The clinical epidemiology of pulmonary cryptococcosis in non-AIDS patients at a tertiary care medical center. Medicine (Baltimore) 2001; 80:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/28\">",
"      Mueller NJ, Fishman JA. Asymptomatic pulmonary cryptococcosis in solid organ transplantation: report of four cases and review of the literature. Transpl Infect Dis 2003; 5:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/29\">",
"      Tashiro T, Nagai H, Nagaoka H, et al. Trichosporon beigelii pneumonia in patients with hematologic malignancies. Chest 1995; 108:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/30\">",
"      Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/31\">",
"      Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009; 48:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/32\">",
"      Ison MG, Hayden FG. Viral infections in immunocompromised patients: what's new with respiratory viruses? Curr Opin Infect Dis 2002; 15:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/33\">",
"      Machado CM, Boas LS, Mendes AV, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant 2003; 31:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/34\">",
"      Triebwasser JH, Harris RE, Bryant RE, Rhoades ER. Varicella pneumonia in adults. Report of seven cases and a review of literature. Medicine (Baltimore) 1967; 46:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/35\">",
"      Escalante CP, Rubenstein EB, Rolston KV. Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients with cancer. Cancer Invest 1997; 15:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21273/abstract/36\">",
"      WEBER DM, PELLECCHIA JA. VARICELLA PNEUMONIA: STUDY OF PREVALENCE IN ADULT MEN. JAMA 1965; 192:572.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1402 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-DBEF2E8A07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_49_21273=[""].join("\n");
var outline_f20_49_21273=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H53648202\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Host susceptibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATTERNS OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Community-acquired infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hospital-acquired (nosocomial) or healthcare-associated infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Environmental exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Reactivation infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Bacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fungi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pneumocystis jirovecii",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Aspergillus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Cryptococcus species",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Candida species",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Agents of mucormycosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other fungi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Viruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Community-acquired respiratory viruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H413855640\">",
"      - SARS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Herpes simplex and varicella zoster viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Parasites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Strongyloides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Toxoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53648202\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/21/29018?source=related_link\">",
"      Antifungal susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18055?source=related_link\">",
"      Candida infections of the abdomen and thorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=related_link\">",
"      Central nervous system tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=related_link\">",
"      Clinical manifestations and diagnosis of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37305?source=related_link\">",
"      Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=related_link\">",
"      Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=related_link\">",
"      Cryptococcal infection outside the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36249?source=related_link\">",
"      Diagnosis and treatment of Scedosporium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33302?source=related_link\">",
"      Epidemiology and clinical manifestations of Penicillium marneffei infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32680?source=related_link\">",
"      Epidemiology and pathogenesis of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27145?source=related_link\">",
"      Epidemiology and pathogenesis of Pseudomonas aeruginosa infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=related_link\">",
"      Epidemiology of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=related_link\">",
"      Human metapneumovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37160?source=related_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23991?source=related_link\">",
"      Microbiology, epidemiology, and pathogenesis of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=related_link\">",
"      Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/617?source=related_link\">",
"      Parainfluenza viruses in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2889?source=related_link\">",
"      Prophylaxis against Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=related_link\">",
"      Pulmonary complications after allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17753?source=related_link\">",
"      Severe acute respiratory syndrome (SARS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=related_link\">",
"      Strongyloidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=related_link\">",
"      Toxoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=related_link\">",
"      Tuberculosis in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_49_21274="Hematopoietic cell transplantation in classical Hodgkin lymphoma";
var content_f20_49_21274=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematopoietic cell transplantation in classical Hodgkin lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/49/21274/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/49/21274/contributors\">",
"     George P Canellos, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/49/21274/contributors\">",
"     Peter M Mauch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/49/21274/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/49/21274/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/49/21274/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/49/21274/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/49/21274/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with early Hodgkin lymphoma (formerly called Hodgkin's disease) who undergo initial remission induction with radiotherapy alone, the rate of relapse is approximately 20 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/1\">",
"     1",
"    </a>",
"    ]. Among patients who undergo initial remission induction with chemotherapy, the rate of relapse ranges from 10 to 15 percent in favorable prognosis stage I-II disease (when combined with radiation therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/2\">",
"     2",
"    </a>",
"    ] to 30 to 40 percent in advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/1,3-6\">",
"     1,3-6",
"    </a>",
"    ]. In addition, approximately 10 to 15 percent of patients experience progression of disease after an initial partial response.",
"   </p>",
"   <p>",
"    Patients with Hodgkin lymphoma relapsing after prior treatment with chemotherapy are generally treated with either conventional chemotherapy combined with radiation therapy or high dose chemotherapy and autologous hematopoietic cell transplantation (HCT) given with or without radiation therapy. The choice of therapy is usually based upon prognostic features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a localized, asymptomatic relapse occurring more than 12 months after initial treatment are usually treated with conventional salvage chemotherapy, often combined with radiation therapy with or without high dose chemotherapy and autologous HCT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\", section on 'Late first relapse'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High dose chemotherapy and autologous HCT should be considered as the treatment of choice for the following subsets of patients:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Early relapse (less than 12 months after treatment) or induction failure.",
"     </li>",
"     <li>",
"      Second relapse after conventional treatment for first relapse.",
"     </li>",
"     <li>",
"      Generalized systemic relapse even beyond 12 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Issues related to high dose chemotherapy followed by hematopoietic cell transplantation (HCT) will be reviewed here. The general approach to the treatment of patients with Hodgkin lymphoma who relapse after initial chemotherapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=see_link\">",
"     \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS AFTER INITIAL RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes in patients with relapsed Hodgkin lymphoma (HL) are at least partially dependent upon the type of initial therapy administered, the duration of response to initial therapy, and disease stage. Patients with favorable prognosis stage I-II Hodgkin lymphoma treated with radiotherapy alone have a higher rate of relapse than, but a similar survival to, those treated with combined therapy (",
"    <a class=\"graphic graphic_figure graphicRef75274 \" href=\"UTD.htm?23/10/23726\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/2\">",
"     2",
"    </a>",
"    ]. The sensitivity to chemotherapy and radiation that is characteristic of Hodgkin lymphoma is similar at the time of initial therapy and at the time of relapse from radiotherapy, and salvage chemotherapy can achieve durable responses and remissions in greater than 60 percent of these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7784?source=see_link\">",
"     \"Relapse of classical Hodgkin lymphoma after initial radiotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The outcome is less good in patients who relapse after initial remission induction with chemotherapy for advanced disease. Among this group, a number of prognostic factors for survival after salvage chemotherapy have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. Limited extent of disease and a complete response duration prior to relapse of greater than 12 months are the most favorable. In one study from the Milan Cancer Institute, for example, the eight-year survival rate was 54 and 28 percent in patients whose initial complete remissions lasted more than or less than 12 months, respectively, and was 8 percent in those failing to achieve complete remission (ie, induction failures) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have described the risk as a function of the number of adverse factors present.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Cancer Control Agency of British Columbia analyzed a series of 80 patients who relapsed after primary systemic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/8\">",
"       8",
"      </a>",
"      ]. Three negative prognostic factors for outcome of second-line therapy were identified: duration of first remission less than 12 months; initial stage IV disease; and B symptoms at relapse. The second failure-free survival rate at a median follow-up of 75 months was 17 percent in patients with any one of these factors compared with 82 percent in patients with no unfavorable factors.",
"     </li>",
"     <li>",
"      Another report evaluated 187 patients who relapsed following primary radiation therapy or chemotherapy for a variety of initial factors [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/9\">",
"       9",
"      </a>",
"      ]. Multivariate analysis indicated that freedom from second failure was adversely affected by first remission duration less than 12 months and stage III-IV at relapse. The five-year relapse-free survival (RFS) and overall survival (OS) were calculated according to the number of these negative factors. Patients with 0, 1 and 2 factors had a RFS of 62, 47, and 32 percent, respectively, and an OS of 87, 59, and 44 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRIMARY REFRACTORY HODGKIN LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractory disease represents a failure to achieve a complete response (CR) or partial response (PR) from chemotherapy or radiation. The incidence of initial treatment failure is unknown, however, a review of 3807 patients with Hodgkin lymphoma treated in chemotherapy protocols of the German Hodgkin's Lymphoma Study Group identified 239 patients who progressed during initial chemotherapy (6.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/11\">",
"     11",
"    </a>",
"    ]. Of this number, 153 received salvage chemotherapy, in whom a CR or PR was achieved in 43 percent, and 38 patients received salvage radiotherapy, 66 percent of whom had a CR or PR. Seventy patients who responded to salvage therapy went on to receive high dose chemotherapy with autologous hematopoietic cell transplantation (HDT-autoHCT). With a median observation time of 52 months, the five-year freedom from second treatment failure and overall survival for all patients undergoing any salvage therapy was 17 and 26 percent, respectively. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients who respond to second line treatment have a much better response to HDT-autoHCT than those with lesser responses. This was shown in a series of 75 patients with primary refractory disease who underwent conventional dose second-line cytoreductive therapy followed by HDT-autoHCT [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/12\">",
"     12",
"    </a>",
"    ]. At a median follow-up of 10 years, patients with chemosensitive or refractory disease to second line chemotherapy had overall survivals following HDT-autoHCT of 66 versus 17 percent, respectively (hazard ratio 4.3).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TRANSPLANTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20737380\">",
"    <span class=\"h2\">",
"     Recurrent or refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;High dose chemotherapy and autologous hematopoietic cell transplantation can achieve sustained remissions in many patients with recurrent or refractory Hodgkin lymphoma. In the absence of randomized trials, a number of important issues remain unresolved concerning this approach including patient selection, choice of procedure, cytoreductive therapy, and the use of adjunctive radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/13\">",
"     13",
"    </a>",
"    ]. In view of the five percent early mortality and the appreciable risk of late myelodysplastic syndrome",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute myeloid leukemia associated with high dose chemotherapy and transplantation, this approach should be considered as a treatment of choice only in patients with a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High dose chemotherapy and autologous HCT should be considered as the treatment of choice for the following subsets of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Early relapse (less than 12 months after treatment) or induction failure.",
"     </li>",
"     <li>",
"      Second relapse after conventional treatment for first relapse.",
"     </li>",
"     <li>",
"      Generalized systemic relapse even beyond 12 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     High risk patients in first remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of autologous hematopoietic cell transplantation in high risk patients with advanced disease in first remission is controversial and investigational [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several schemes for identifying patients at high risk of relapse following chemotherapy (with or without radiotherapy) for advanced Hodgkin lymphoma have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The largest came from the International Prognostic Factors Project on Advanced Hodgkin lymphoma involving 5141 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/19\">",
"     19",
"    </a>",
"    ]. Seven adverse prognostic factors were identified: stage IV disease, male sex, age greater than 45, hemoglobin concentration less than 10.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (105",
"    <span class=\"nowrap\">",
"     g/L),",
"    </span>",
"    white blood count",
"    <span class=\"nowrap\">",
"     &ge;15,000/&micro;L,",
"    </span>",
"    lymphocyte count less than",
"    <span class=\"nowrap\">",
"     600/&micro;L",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    less than 8 percent of the white blood cell count, and serum albumin concentration less than 4",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (40",
"    <span class=\"nowrap\">",
"     g/L),",
"    </span>",
"    each of which contributed about a 7 percent reduction in freedom from progression at five years. When five to seven adverse factors were present, one of which included age greater than 45 years, freedom from progression at five years fell to 42 percent (compared with 84 and 77 percent when none or one of these factors was present). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link&amp;anchor=H9398216#H9398216\">",
"     \"Staging and prognosis of Hodgkin lymphoma\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the last group might be considered at very high risk for recurrence (58 percent), it constituted only 7 percent of the total patient population. Thus, randomized trials require international collaboration to evaluate new therapies in these patients. In this regard, the International Prognostic Factors Project score outlined above for patients undergoing chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/19\">",
"     19",
"    </a>",
"    ] has also been found to be useful for predicting clinical outcomes in patients with relapsed or refractory disease undergoing high-dose therapy followed by autologous transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two prospective randomized trials, comparing high dose chemotherapy and autologous transplantation versus conventional therapy in patients with advanced Hodgkin lymphoma responding to initial chemotherapy have been reported, one in preliminary form, and do not show a survival benefit for the transplantation arm [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Accordingly, up front high-dose chemotherapy and hematopoietic stem cell rescue is not being recommended even in those patients who have five to seven adverse features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HIGH DOSE CHEMOTHERAPY AND TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the early transplant literature, most centers now perform autologous hematopoietic cell transplantation with a less than 5 percent rate of early mortality and relapse rates approximating 40 to 50 percent.",
"   </p>",
"   <p>",
"    Initial allogeneic transplants are generally not recommended because of the superimposition of graft-versus-host disease and other causes of early mortality, which can be a major problem in these severely ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/23\">",
"     23",
"    </a>",
"    ]. The difference in outcome was illustrated by a study from the European Group for Blood and Bone Marrow Transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/24\">",
"     24",
"    </a>",
"    ]. Among 90 patients with chemotherapy-sensitive disease at the time of transplant, survival was higher in patients receiving autologous transplantation (64 versus 30 percent with allogeneic transplantation, p = 0.007) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/24\">",
"     24",
"    </a>",
"    ]. This difference was largely due to increased transplant-related mortality with allogeneic transplants (65 versus 12 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of large trials with selected patients have indicated an event-free survival of 35 to 60 percent at five years for patients transplanted after first relapse&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/25-31\">",
"     25-31",
"    </a>",
"    ]. The outcome varies in part with the initial response to therapy (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Prognostic factors for recurrence after transplantation'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients who achieve an initial complete remission, five-year progression-free survival following high-dose therapy ranges from 47 to 60 percent for patients whose initial remission exceeded 12 months compared with 32 percent for those whose initial remission was &lt;12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A worse outcome has been noted in patients who fail to achieve an initial complete response to induction therapy. The reported event-free survival following autologous hematopoietic cell transplantation in such patients ranged from 34 to 38 percent at three years [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/28,30\">",
"       28,30",
"      </a>",
"      ] and 32 percent at five years [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/31-33\">",
"       31-33",
"      </a>",
"      ]. Overall survival has ranged from 50 percent at three years [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/30\">",
"       30",
"      </a>",
"      ] to 36 percent at five years [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The general value of high-dose therapy and transplantation is difficult to interpret because of patient selection bias and the paucity of randomized trials. There are indications that autologous hematopoietic cell transplantation may produce results similar to conventional therapy in patients with favorable prognostic factors and may be of most benefit in patients with poor prognostic factors for survival with conventional therapy (ie, refractory disease or complete remission duration of less than 12 months.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study compared 60 patients in first relapse or with refractory disease treated with high dose chemotherapy and autologous transplantation to a matched group of similar patients treated with conventional salvage therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/29\">",
"       29",
"      </a>",
"      ]. Event-free survival and progression-free survival were superior in the transplantation group (53 versus 27 percent and 62 versus 32 percent, respectively). However, there was no significant difference in overall survival (54 versus 47 percent). The benefit of high-dose therapy was most pronounced and significant for all three survival measures in patients with less favorable prognostic factors (refractory disease or complete remission of less than 12 months).",
"     </li>",
"     <li>",
"      The British National Lymphoma Investigation began a prospective randomized study of high dose BEAM (BCNU,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      [Ara-C],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      ) and autologous transplantation compared with mini-BEAM (conventional doses) in patients with high-risk Hodgkin lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/25\">",
"       25",
"      </a>",
"      ]. The three-year actuarial event-free survival was significantly higher in the transplanted group (53 versus 10 percent), resulting in termination of the trial. However, a difference in overall survival was not shown for this or a similar randomized study [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective case control study matched 86 patients treated with autologous transplantation for induction failure with 258 conventionally treated patients from international databases [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/35\">",
"       35",
"      </a>",
"      ]. With a median follow-up of 22 months from diagnosis, there was a trend toward improved six-year overall survival of the transplant recipients (38 versus 29 percent, p = 0.058).",
"     </li>",
"     <li>",
"      In the experience of the German Hodgkin's Lymphoma Study Group of 70 patients with refractory Hodgkin lymphoma who underwent high dose chemotherapy with hematopoietic cell transplant, the five-year freedom from second failure and overall survival were 31 and 43 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/11\">",
"       11",
"      </a>",
"      ]. The four-year freedom from second relapse and overall survival in patients treated with salvage radiotherapy alone was 22 and 52 percent, respectively, with 23 percent alive and in continuous CR with a median of 34 months follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Seven publications summarizing the experience with autologous transplantation in over 1000 patients have shown a consistent long-term benefit in progression-free survival of 49 to 53 percent at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/7,36-41\">",
"     7,36-41",
"    </a>",
"    ]. Consistent adverse prognostic factors among these series continue to be: chemoresistance prior to transplant, active residual disease with B symptoms, and early relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cytoreductive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytoreductive therapy to reduce tumor burden is conventionally given prior to high dose chemotherapy (HDT), but the impact of this strategy on disease-free survival has not been demonstrated in controlled studies. In single arm studies, disease status at the time of transplantation is an important predictor of survival and of time to treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/27,42,43\">",
"     27,42,43",
"    </a>",
"    ]. As an example, in one series of 494 patients with HL undergoing HDT with autologous hematopoietic cell rescue, the five-year relapse-free survival was 63, 37, and 17 percent for those patients entering transplantation with a complete remission, chemotherapy-sensitive disease, or drug-resistant disease, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/42\">",
"     42",
"    </a>",
"    ]. However, this relationship may only reflect the drug sensitivity of the tumor.",
"   </p>",
"   <p>",
"    The choice of conventional cytoreductive therapy is generally based upon prior treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/27\">",
"     27",
"    </a>",
"    ]. For example, patients who relapse within 12 months of exposure to a single four-drug regimen such as ABVD are treated with a combination such as MOPP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\", section on 'Chemotherapy'",
"    </a>",
"    .) If, on the other hand, disease progression occurs within 12 months of a seven or eight drug regimen, a typical regimen is DHAP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , high-dose Ara-C,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [Platinol&reg;]). Some of the newer second-line regimens, such as ESHAP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , cisplatin), ASHAP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , cisplatin, cytarabine, methylprednisolone), and ICE (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , etoposide) have also been used in cytoreductive protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38009?source=see_link\">",
"     \"Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal of cytoreductive therapy is to achieve a minimal disease state prior to transplantation. Patients who do not regress may receive two or more cytoreductive regimens prior to their receiving the preparative regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Preparative regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common preparative regimens prior to transplantation in Hodgkin lymphoma are CBV (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , BCNU [",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    [VP-16]) and BEAM (BCNU, etoposide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    [Ara-C], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ). Fractionated total body radiation has often been given in conjunction with etoposide and cyclophosphamide. However, this approach is used less often because of concern about pulmonary toxicity in patients with a history of mantle radiation or chemical or radiation pneumonitis, or in patients with impaired pulmonary diffusing capacity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link\">",
"     \"Preparative regimens for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some centers use CCNU (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/27/37302?source=see_link\">",
"     lomustine",
"    </a>",
"    ) as an alternative to BCNU, because of a lower incidence of respiratory complications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/27,47\">",
"     27,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28327?source=see_link\">",
"     \"Nitrosourea-induced pulmonary injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Variations in the myeloablative regimens have included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sequential high-dose chemotherapy and BEAM [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      High dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Total lymphoid irradiation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There did not seem to be an advantage of any of these over prior regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Choice of donor cell",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous peripheral blood stem cells (PBSCs) are the donor cells of choice because of more rapid hematologic recovery and shortened hospital stay when compared with autologous bone marrow transplantation (auto-BMT) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, a multicenter trial randomly assigned 58 patients with advanced Hodgkin lymphoma or high-grade non-Hodgkin lymphoma to receive filgrastim-mobilized PBSCs or auto-BMT for hematopoietic reconstitution [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients treated with PBSCs experienced reductions in the time to neutrophil recovery (11 versus 14 days) and platelet recovery (16 versus 23 days), and in hospital stay (17 versus 23 days). Early posttransplant morbidity and overall survival at a mean of almost one year were similar in both groups. Economic analysis revealed a cost saving of $13,521 (23 percent) per patient associated with PBSCs, largely due to the reduced hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, most of the benefits from the use of PBSCs disappear when this procedure is compared with filgrastim-primed auto-BMT. In a randomized trial comparing these two approaches in patients with lymphoma, the only significant difference was a slightly shorter time to platelet recovery in patients receiving PBSCs (14 versus 16 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two retrospective studies used matched-pair analysis to compare long-term survival in patients undergoing these procedures. In a series of 256 patients with Hodgkin lymphoma from the European Blood and Marrow Transplant Group Registry, overall survival (65 versus 53 percent, p = 0.02) and progression free survival were better for auto-BMT compared with PBSCs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/49\">",
"     49",
"    </a>",
"    ]. This difference was viewed as surprising and unexplained and was not confirmed in a report of 70 patients treated at a single center with the same conditioning regimen. However, there was a trend toward lower overall survival with auto-BMT (69 versus 79 percent, p = 0.08) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adjunctive radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant involved-field irradiation is widely used either before or after autologous hematopoietic cell transplantation, especially for patients with a positive positron emission tomography (PET) scan prior to transplantation. There are no randomized trials indicating survival benefit, but several studies have shown that adjuvant irradiation can control limited residual disease and may contribute to improved prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/54-57\">",
"     54-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 73 patients with relapsed Hodgkin lymphoma, 43 had involved-field radiation therapy as a component of the salvage therapy, usually prior to high-dose therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/54\">",
"       54",
"      </a>",
"      ]. Bulky (greater than 5 cm) sites of relapse were treated routinely. Univariate analysis showed that radiation therapy was associated with a significantly improved prognosis, but its independent influence was lost in multivariate analysis, probably because of linkage to \"non-bulky\" or disease-free status at the time of high-dose therapy.",
"     </li>",
"     <li>",
"      In a report of 100 patients with relapsed or refractory Hodgkin lymphoma, 24 received irradiation to a total of 67 involved sites before or after transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/55\">",
"       55",
"      </a>",
"      ]. At follow-up, relapse was identified in only four of the irradiated sites. Among patients with relapse stage I-III disease, the use of involved-field radiotherapy was associated with an improved three-year freedom-from-relapse (FFR) (100 versus 67 percent) and a trend toward improved survival. Among 39 patients with no prior history of radiation therapy, involved-field irradiation (n =14) was associated with improved three-year survival (93 versus 55 percent) and a tendency toward improved three-year FFR (85 versus 57 percent, p = 0.07). When the two criteria were combined (ie, patients with relapse stage I-III and no prior history of irradiation), all survival indices were significantly better among those patients who had involved-field irradiation as a component of the high dose therapy.",
"     </li>",
"     <li>",
"      The use of involved-field radiation therapy followed by hyperfractionated total lymphoid irradiation prior to high-dose therapy was evaluated in 47 patients with relapsed Hodgkin lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/58\">",
"       58",
"      </a>",
"      ]. Following cytoreduction with conventional chemotherapy, the patients underwent a course of irradiation including involved-field treatment to a dose of 15 Gy in 10 fractions over five days (twice a day fractionation) followed by total lymphoid irradiation to 20 Gy in 12 fractions over four days (three times a day fractionation). This was followed by high dose chemotherapy and auto-BMT. The following results were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fifty-three percent were alive and without evidence of disease at a median follow-up of 40 months.",
"     </li>",
"     <li>",
"      The actuarial disease-free survival (DFS) rate for the entire group was 50 percent at 6.5 years. The DFS was higher in patients treated for relapsing disease compared with those treated for refractory disease (79 versus 33 percent).",
"     </li>",
"     <li>",
"      There were eight toxic deaths (17 percent).",
"      <br/>",
"      <br/>",
"      However, this approach requires caution, especially due to potential lung toxicity associated with the large mediastinal fields treated so shortly before high dose chemotherapy. As experience with this regimen has become greater, the treatment-related mortality has decreased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Development of MDS or AML",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important problem with the use of autologous hematopoietic cell transplantation for lymphoid malignancies is the development of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The estimated actuarial frequency of this complication is 9 to 18 percent at five to seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/13,59-63\">",
"     13,59-63",
"    </a>",
"    ], with a short median time to onset of two to four years. On the other hand, the risk of developing secondary",
"    <span class=\"nowrap\">",
"     MDS/AML",
"    </span>",
"    appears to be much less following allogeneic transplantation for HL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/23,64\">",
"     23,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clonal cytogenetic abnormalities in these patients, which are typically not present prior to transplantation, are characteristic of those described in therapy-related MDS: abnormalities in chromosome 5 or 7 (as seen with alkylating agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy); and abnormalities in 11q23 or 21q22 (as seen with topoisomerase-II inhibitors) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. These observations suggest that prior lymphoma treatment and the preparative regimen for transplantation contribute to the development of MDS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link&amp;anchor=H13#H13\">",
"     \"Cytogenetics in acute myeloid leukemia\", section on 'Therapy-related myeloid neoplasms (t-MDS/t-AML)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One report evaluated 612 patients who received autologous hematopoietic cell transplantation (HCT) for Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/61\">",
"     61",
"    </a>",
"    ]. The estimated cumulative probability of therapy-related",
"    <span class=\"nowrap\">",
"     MDS/AML",
"    </span>",
"    was 8.6 percent at six years. The relative risk of this complication was 7.7 in patients who received chemotherapy priming with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .) Multivariate analysis revealed an association with pretransplant radiation but not pretransplant chemotherapy or conditioning regimen.",
"   </p>",
"   <p>",
"    A second, multicenter case-control study of 2739 patients receiving autologous HCT for HL or NHL found a similar incidence of therapy-related",
"    <span class=\"nowrap\">",
"     MDS/AML",
"    </span>",
"    (8.1 percent at seven years) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/62\">",
"     62",
"    </a>",
"    ]. A significantly increased incidence of this complication was found following total body irradiation (TBI) doses &gt;13.2 Gy (relative risk (RR) 4.6), treatment with higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    (&ge;50",
"    <span class=\"nowrap\">",
"     mg/m(2),",
"    </span>",
"    RR 4.3) and prolonged treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    (&ge;10 months, RR 8.4). These observations may be less relevant now that TBI is rarely used in the autologous HCT regimen and mechlorethamine and chlorambucil are less frequently used as first-line treatment of HL and NHL.",
"   </p>",
"   <p>",
"    Patients who have cytogenetic abnormalities before transplantation appear to be at particularly high risk of MDS or acute leukemia after transplantation. In one report of seven such patients, MDS or acute leukemia occurred in all three who were transplanted (compared with 9 to 18 percent in all transplants); four patients who had the clonal abnormality detected before bone marrow harvest did not proceed to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/65\">",
"     65",
"    </a>",
"    ]. As a result, it has been suggested that patients with recurrent Hodgkin lymphoma should undergo bone marrow biopsy for both morphologic and cytogenetic analysis before bone marrow harvest if high-dose therapy and autologous transplantation are being considered.",
"   </p>",
"   <p>",
"    The issue of long-term toxicity following autologous HCT is controversial. A French series implied an increase in solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/66\">",
"     66",
"    </a>",
"    ], while an analysis from British Columbia suggested that there was no increase in second tumors compared with conventional dose therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/67\">",
"     67",
"    </a>",
"    ]. The incidence of second tumors in both series was 9 percent, while the incidence of",
"    <span class=\"nowrap\">",
"     MDS/AML",
"    </span>",
"    was increased in patients &gt;35 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS FOR RECURRENCE AFTER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, relapse occurs in 40 to 50 percent of patients after high dose chemotherapy and transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/25-30\">",
"     25-30",
"    </a>",
"    ]. A number of risk factors for recurrence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduced survival after HDT-autoHCT have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration of CR of less than 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/20,26,27,36,68\">",
"       20,26,27,36,68",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chemotherapy resistant disease (induction failure or resistant relapse) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/28,30,69,70\">",
"       28,30,69,70",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increasing number of failed chemotherapy regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/69-73\">",
"       69-73",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      More than minimal disease at transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bulky residual disease at transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/54,70,71\">",
"       54,70,71",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      B symptoms at relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/27,68,71,72,74\">",
"       27,68,71,72,74",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Extranodal disease at relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/27,68,70,72,74\">",
"       27,68,70,72,74",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Poor performance status [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/73\">",
"       73",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Relapse within a prior radiation field [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/54\">",
"       54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Slow recovery of absolute lymphocyte count post-transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/75\">",
"       75",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      High International Prognostic Factors Project score [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Status of PET scan after salvage chemotherapy but prior to ASCT [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/76-78\">",
"       76-78",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prognostic factor indices have been developed utilizing the presence or absence of risk factors. In a retrospective review of 119 patients with Hodgkin lymphoma who were transplanted for relapsed or refractory disease, regression analysis identified systemic symptoms at relapse, disseminated pulmonary or bone marrow disease at relapse, and more than minimal disease at the time of transplantation as significantly negative prognostic factors for overall survival and freedom from progression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/27\">",
"     27",
"    </a>",
"    ]. The freedom from progression (FFP) in patients with none, one, two, or three of these factors was 85, 57, 41, and 20 percent respectively. The four-year FFP for patients with no unfavorable factors (n = 46) was 85 percent compared with 41 percent for patients with one or more (n = 68).",
"   </p>",
"   <p>",
"    A study of 280 patients selected from the French Registry for Bone Marrow Transplantation identified two adverse prognostic factors: complete remission duration of less than 12 months and extranodal (versus nodal) relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/79\">",
"     79",
"    </a>",
"    ]. Four-year survival in patients with zero, one, or two factors was 93, 59, and 43 percent respectively.",
"   </p>",
"   <p>",
"    The emergence of FDG-PET scans in the assessment of response has added to the predictive parameters in HL. Patients achieving a second-line CR with a negative FDG-PET have a 75 percent rate of salvage with ASCT. These data are derived from relatively small numbers of patients but similar responses in non-Hodgkin lymphomas also suggest a greater long-term benefit from salvage ASCT in FDG-PET-negative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/43,76,80\">",
"     43,76,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT OF RELAPSE FOLLOWING TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who relapse systemically following high-dose therapy and autologous hematopoietic cell transplantation (HCT) have limited treatment options because of their limited bone marrow reserve. Only highly selected patients can tolerate a second autologous transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/81\">",
"     81",
"    </a>",
"    ]. Single agent chemotherapy is often used in this setting, but there are no guidelines for the selection of agents. Other options include the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/6/16486?source=see_link\">",
"     brentuximab vedotin",
"    </a>",
"    , local regional irradiation, or allogeneic HCT. The use of chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    brentuximab is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38009?source=see_link&amp;anchor=H15846182#H15846182\">",
"     \"Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma\", section on 'Brentuximab vedotin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective analysis of 71 patients who developed progressive disease after receiving an autologous HCT for relapsed or primary refractory HL reported a median survival of 25 months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/82\">",
"     82",
"    </a>",
"    ]. At a median follow-up of 46 months, 16 patients (23 percent) were still alive, 9 of whom were in remission. The following treatments were initiated with the identification of progression:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    -based chemotherapy (63 percent), MOPP (39 percent), radiation (13 percent) or a second HCT (34 percent). When compared with those who received other therapies, patients receiving a second HCT (allogeneic or autologous) had a significantly higher median survival (40 versus 19 months).",
"   </p>",
"   <p>",
"    Resistance, defined as failure to regress or progression on therapy, usually demands the use of agents of differing mechanism of action. The use of single agents is employed in the setting of resistance to the more standard MOPP-derived and ABVD-derived regimens, including second- and third-line combinations containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38009?source=see_link\">",
"     \"Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compromised bone marrow reserve might justify the use of single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , an agent that was associated with an objective response rate of 59 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/83\">",
"     83",
"    </a>",
"    ]. Other single agents that have been evaluated include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ; the frequency of partial responses ranged from 17 to 35 percent with a duration of response of two to eight months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/84-88\">",
"     84-88",
"    </a>",
"    ]. These drugs can be used in sequence as tolerated.",
"   </p>",
"   <p>",
"    Failure of autologous HCT may be salvaged by allogeneic HCT with two-year progression-free survival of approximately 40 percent in highly select patient populations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Non-myeloablative allogeneic HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative approach is use of reduced-intensity (nonmyeloablative) conditioning followed by allogeneic hematopoietic cell transplantation, which has shown evidence of a graft-versus-tumor effect in Hodgkin lymphoma (HL) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/89-98\">",
"     89-98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial experience with non-myeloablative HCT in HL came from patients with multiply-relapsed HL [",
"    <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/90,95,99\">",
"     90,95,99",
"    </a>",
"    ]. Retrospective studies and case series have reported on the use of nonmyeloablative HCT in relapsed HL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective Italian study of 185 patients with relapsed HL after autologous HCT who underwent HLA typing in preparation for an allogeneic HCT reported that 122 patients (66 percent) had a suitable donor, 104 of whom proceeded with allogeneic HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/89\">",
"       89",
"      </a>",
"      ]. In an intention-to-treat analysis, patients with either a matched sibling, a matched unrelated donor, or a haploidentical sibling had significantly higher rates of progression free (39 versus 14 percent) and overall survival (66 versus 42 percent) at two years when compared with patients who did not have an HLA match.",
"     </li>",
"     <li>",
"      Another retrospective series reported outcomes of 168 patients with relapsed HL treated with myeloablative (79 patients) or nonmyeloablative (89 patients) conditioning regimens for their first allogeneic HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/97\">",
"       97",
"      </a>",
"      ]. Patients who received a nonmyeloablative conditioning regimen had significantly better rates of one-year non-relapse mortality (23 versus 46 percent) and five-year overall survival (28 versus 22 percent).",
"     </li>",
"     <li>",
"      In one trial, 49 patients with multiply-relapsed HL, 90 percent of whom had disease progression after a prior autologous HCT, underwent non-myeloablative HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/90\">",
"       90",
"      </a>",
"      ]. All patients engrafted, with non-relapse mortality of 4.1 and 16 percent at 100 days and two years, respectively. Nine of 16 patients showed disease response (8 complete, 1 partial) following donor lymphocyte infusion. Projected four-year overall and progression-free survivals were 56 and 39 percent, respectively.",
"      <br/>",
"      <br/>",
"      Another report from the same group of an expanded population of 76 patients with multiply-relapsed or refractory HL who underwent non-myeloablative allogeneic HCT with in vivo T-cell depletion with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      reported four-year overall and progression-free survival rates of 64 and 59 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/100\">",
"       100",
"      </a>",
"      ]. Escalating doses of donor lymphocyte infusions (DLIs) were given to 22 patients for mixed chimerism and to 24 patients with relapse. Overall and complete responses were seen in 79 and 64 percent of patients receiving DLI for relapse, respectively. Those patients who received a DLI for mixed chimerism had a significantly lower rate of relapse at four years (5 versus 43 percent) when compared with those who had a full donor chimera at nine months. &nbsp;",
"     </li>",
"     <li>",
"      A series from Spain of nonmyeloablative HCT in 40 patients showed encouraging results in those relapsing &gt;12 months following autologous HCT, with a two-year PFS of 70 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?20/49/21274/abstract/92\">",
"       92",
"      </a>",
"      ]. However, overall PFS was 32 percent at two years with a TRM of 25 percent. Chemoresistant patients had a PFS of 10 percent, while it was 55 percent in those with chemosensitive disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These reports suggest that nonmyeloablative HCT has a lower rate of acute toxicity than full myeloablative allogeneic HCT, but with unclear long term benefits. In patients with relapsed HL, the first salvage therapy of choice is autologous HCT. If this approach fails, nonmyeloablative allogeneic HCT or myeloablative allogeneic HCT may be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       \"Patient information: Bone marrow transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=see_link\">",
"       \"Patient information: Hodgkin lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20737290\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High dose chemotherapy and autologous hematopoietic cell transplantation (HCT) is considered the treatment of choice for the following subsets of patients (see",
"      <a class=\"local\" href=\"#H20737380\">",
"       'Recurrent or refractory disease'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Early relapse (less than 12 months after treatment) or induction failure",
"     </li>",
"     <li>",
"      Second relapse after conventional treatment for first relapse",
"     </li>",
"     <li>",
"      Generalized systemic relapse even beyond 12 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of autologous HCT in high risk patients with advanced disease in first remission is controversial and investigational. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'High risk patients in first remission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to the early transplant literature, most centers now perform autologous HCT with a 5 to 10 percent early mortality and relapse rates approximating 40 to 50 percent. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cytoreductive therapy to reduce tumor burden is conventionally given prior to high dose chemotherapy (HDT), but the impact of this strategy on disease-free survival has not been demonstrated in controlled studies. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cytoreductive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best preparative regimen prior to HCT in Hodgkin lymphoma is unknown. The most common preparative regimens are CBV (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , BCNU [",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"       carmustine",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      [VP-16]) and BEAM (BCNU, etoposide,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      [Ara-C], and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Preparative regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autologous peripheral blood stem cells are the donor cells of choice because of more rapid hematologic recovery and shortened hospital stay when compared with autologous bone marrow transplantation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Choice of donor cell'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adjuvant involved-field irradiation is widely used either before or after autologous HCT. Several studies have shown that adjuvant irradiation can control limited residual disease and may contribute to improved prognosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Adjunctive radiotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who undergo autologous HCT develop myelodysplastic syndrome or acute myeloid leukemia at an estimated actuarial frequency of 9 to 18 percent at five to seven years, with a short median time to onset of two to four years. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Development of MDS or AML'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who relapse following high-dose therapy and autologous HCT usually have limited bone marrow reserve. Treatment options include single agent chemotherapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/6/16486?source=see_link\">",
"       brentuximab vedotin",
"      </a>",
"      , local regional irradiation, repeat autologous HCT, or reduced-intensity (nonmyeloablative) conditioning followed by allogeneic HCT. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment of relapse following transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/1\">",
"      Oza AM, Ganesan TS, Leahy M, et al. Patterns of survival in patients with Hodgkin's disease: long follow up in a single centre. Ann Oncol 1993; 4:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/2\">",
"      Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998; 16:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/3\">",
"      Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/4\">",
"      Somers R, Carde P, Henry-Amar M, et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994; 12:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/5\">",
"      Radford JA, Crowther D, Rohatiner AZ, et al. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol 1995; 13:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/6\">",
"      Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 1996; 14:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/7\">",
"      Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/8\">",
"      Lohri A, Barnett M, Fairey RN, et al. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood 1991; 77:2292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/9\">",
"      Brice P, Bastion Y, Divine M, et al. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer 1996; 78:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/10\">",
"      Viviani S, Santoro A, Negretti E, et al. Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission. Ann Oncol 1990; 1:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/11\">",
"      Josting A, Rueffer U, Franklin J, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/12\">",
"      Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/13\">",
"      Aisenberg AC. Problems in Hodgkin's disease management. Blood 1999; 93:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/14\">",
"      Mink SA, Armitage JO. High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma. Oncologist 2001; 6:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/15\">",
"      Carella AM, Carlier P, Congiu A, et al. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplant 1991; 8:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/16\">",
"      Nademanee A, Molina A, Fung H, et al. High-dose chemo/radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced-stage Hodgkin's disease during first partial or complete remission. Biol Blood Marrow Transplant 1999; 5:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/17\">",
"      Straus DJ, Gaynor JJ, Myers J, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990; 8:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/18\">",
"      Proctor SJ, Taylor P, Donnan P, et al. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Eur J Cancer 1991; 27:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/19\">",
"      Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/20\">",
"      Bierman PJ, Lynch JC, Bociek RG, et al. The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002; 13:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/21\">",
"      Federico M, Bellei M, Brice P, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 2003; 21:2320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/22\">",
"      Saghatchian M, Djeridane M, Escoffre-barbe M, et al. Very high risk Hodgkin's disease (HD): ABVd (4 cycles) plus BEAM followed by autologous stem cell transplantation (ASCT) and radiotherapy (RT) versus intensive chemotherapy (3 cycles) (INT-CT) and RT. Four-year results of the GOELAMS H97-GM multicentric randomized trial (abstract). Proc ASCO. J Clin Oncol 2002; 21:263a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/23\">",
"      Akpek G, Ambinder RF, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001; 19:4314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/24\">",
"      Milpied N, Fielding AK, Pearce RM, et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996; 14:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/25\">",
"      Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/26\">",
"      Bierman PJ, Anderson JR, Freeman MB, et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Oncol 1996; 7:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/27\">",
"      Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/28\">",
"      Prince HM, Crump M, Imrie K, et al. Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma. Ann Oncol 1996; 7:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/29\">",
"      Yuen AR, Rosenberg SA, Hoppe RT, et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/30\">",
"      Lazarus HM, Rowlings PA, Zhang MJ, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999; 17:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/31\">",
"      Tarella C, Cuttica A, Vitolo U, et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer 2003; 97:2748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/32\">",
"      Sweetenham JW, Carella AM, Taghipour G, et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 1999; 17:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/33\">",
"      Gopal AK, Metcalfe TL, Gooley TA, et al. High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience. Cancer 2008; 113:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/34\">",
"      Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/35\">",
"      Andr&eacute; M, Henry-Amar M, Pico JL, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Soci&eacute;t&eacute; Francaise de Greffe de Moelle. J Clin Oncol 1999; 17:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/36\">",
"      Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005; 16:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/37\">",
"      Josting A, Rudolph C, Mapara M, et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005; 16:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/38\">",
"      Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/39\">",
"      Wadehra N, Farag S, Bolwell B, et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant 2006; 12:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/40\">",
"      Evens AM, Altman JK, Mittal BB, et al. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Ann Oncol 2007; 18:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/41\">",
"      Smith SD, Moskowitz CH, Dean R, et al. Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. Br J Haematol 2011; 153:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/42\">",
"      Sureda A, Arranz R, Iriondo A, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espa&ntilde;ol de Linfomas/Transplante Aut&oacute;logo de M&eacute;dula Osea Spanish Cooperative Group. J Clin Oncol 2001; 19:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/43\">",
"      Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 2010; 148:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/44\">",
"      Aparicio J, Segura A, Garcer&aacute; S, et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 1999; 10:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/45\">",
"      Rodriguez J, Rodriguez MA, Fayad L, et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 1999; 93:3632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/46\">",
"      Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/47\">",
"      Perz JB, Giles C, Szydlo R, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant 2007; 39:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/48\">",
"      Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/49\">",
"      Majolino I, Pearce R, Taghipour G, Goldstone AH. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 1997; 15:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/50\">",
"      Brice P, Marolleau JP, Pautier P, et al. Hematologic recovery and survival of lymphoma patients after autologous stem-cell transplantation: comparison of bone marrow and peripheral blood progenitor cells. Leuk Lymphoma 1996; 22:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/51\">",
"      Smith TJ, Hillner BE, Schmitz N, et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997; 15:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/52\">",
"      Damiani D, Fanin R, Silvestri F, et al. Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. Blood 1997; 90:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/53\">",
"      Perry AR, Peniket AJ, Watts MJ, et al. Peripheral blood stem cell versus autologous bone marrow transplantation for Hodgkin's disease: equivalent survival outcome in a single-centre matched-pair analysis. Br J Haematol 1999; 105:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/54\">",
"      Crump M, Smith AM, Brandwein J, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 1993; 11:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/55\">",
"      Poen JC, Hoppe RT, Horning SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys 1996; 36:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/56\">",
"      Mundt AJ, Sibley G, Williams S, et al. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease. Int J Radiat Oncol Biol Phys 1995; 33:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/57\">",
"      Kahn S, Flowers C, Xu Z, Esiashvili N. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma? Int J Radiat Oncol Biol Phys 2011; 81:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/58\">",
"      Yahalom J, Gulati SC, Toia M, et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 1993; 11:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/59\">",
"      Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/60\">",
"      Traweek ST, Slovak ML, Nademanee AP, et al. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 1994; 84:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/61\">",
"      Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/62\">",
"      Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003; 101:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/63\">",
"      Goodman KA, Riedel E, Serrano V, et al. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. J Clin Oncol 2008; 26:5240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/64\">",
"      Dann EJ, Daugherty CK, Larson RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 20:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/65\">",
"      Chao NJ, Nademanee AP, Long GD, et al. Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease. J Clin Oncol 1991; 9:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/66\">",
"      Andr&eacute; M, Henry-Amar M, Blaise D, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998; 92:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/67\">",
"      Forrest DL, Hogge DE, Nevill TJ, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol 2005; 23:7994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/68\">",
"      Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/69\">",
"      O'Brien ME, Milan S, Cunningham D, et al. High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index. Br J Cancer 1996; 73:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/70\">",
"      Lavoie JC, Connors JM, Phillips GL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/71\">",
"      Burns LJ, Daniels KA, McGlave PB, et al. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: factors predictive of prolonged survival. Bone Marrow Transplant 1995; 16:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/72\">",
"      Nademanee A, O'Donnell MR, Snyder DS, et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 1995; 85:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/73\">",
"      Bierman PJ, Bagin RG, Jagannath S, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol 1993; 4:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/74\">",
"      Reece DE, Barnett MJ, Shepherd JD, et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 1995; 86:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/75\">",
"      Porrata LF, Inwards DJ, Micallef IN, et al. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol 2002; 117:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/76\">",
"      Castagna L, Bramanti S, Balzarotti M, et al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol 2009; 145:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/77\">",
"      Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010; 116:4934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/78\">",
"      Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012; 119:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/79\">",
"      Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Soci&eacute;t&eacute; Fran&ccedil;aise de Greffe de Mo&euml;lle. Bone Marrow Transplant 1997; 20:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/80\">",
"      Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/81\">",
"      Thomson KJ, Peggs KS, Blundell E, et al. A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft. Leuk Lymphoma 2007; 48:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/82\">",
"      Moskowitz AJ, Perales MA, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 2009; 146:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/83\">",
"      Little R, Wittes RE, Longo DL, Wilson WH. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol 1998; 16:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/84\">",
"      Younes A, Cabanillas F, McLaughlin PW, et al. Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease. Ann Oncol 1996; 7:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/85\">",
"      Thomas J, de Pauw B, Hagenbeek A, et al. Phase II study of cytarabine in Hodgkin's disease. The EORTC Lymphoma Cooperative Group. Eur J Cancer 1992; 28A:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/86\">",
"      Devizzi L, Santoro A, Bonfante V, et al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 1994; 5:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/87\">",
"      Tesch H, Santoro A, Fiedler F, et al. Phase II study of gemcitabine in patients with multiple pretreated Hodgkin's disease. Results of a multicenter study. Leuk Lymphoma 1998; 29 Suppl:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/88\">",
"      Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011; 118:5119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/89\">",
"      Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010; 115:3671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/90\">",
"      Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/91\">",
"      Anderlini P, Champlin RE. Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: where do we stand? Biol Blood Marrow Transplant 2006; 12:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/92\">",
"      Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006; 12:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/93\">",
"      Schmitz N, Sureda A. The role of allogeneic stem-cell transplantation in Hodgkin's disease. Eur J Haematol Suppl 2005; :146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/94\">",
"      Thomson KJ, Peggs KS, Smith P, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008; 41:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/95\">",
"      Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007; 139:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/96\">",
"      Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/97\">",
"      Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/98\">",
"      Corradini P, Sarina B, Farina L. Allogeneic transplantation for Hodgkin's lymphoma. Br J Haematol 2011; 152:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/99\">",
"      Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espa&ntilde;ol de Linfomas/Trasplante de M&eacute;dula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012; 97:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/49/21274/abstract/100\">",
"      Peggs KS, Kayani I, Edwards N, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011; 29:971.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4760 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_49_21274=[""].join("\n");
var outline_f20_49_21274=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20737290\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSTIC FACTORS AFTER INITIAL RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRIMARY REFRACTORY HODGKIN LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDICATIONS FOR TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20737380\">",
"      Recurrent or refractory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      High risk patients in first remission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HIGH DOSE CHEMOTHERAPY AND TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cytoreductive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Preparative regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Choice of donor cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adjunctive radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Development of MDS or AML",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROGNOSTIC FACTORS FOR RECURRENCE AFTER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT OF RELAPSE FOLLOWING TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Non-myeloablative allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20737290\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4760\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4760|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/10/23726\" title=\"figure 1\">",
"      RT alone or with chemo early HL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25960?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28327?source=related_link\">",
"      Nitrosourea-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7784?source=related_link\">",
"      Relapse of classical Hodgkin lymphoma after initial radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38009?source=related_link\">",
"      Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=related_link\">",
"      Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_49_21275="Common medical complications of stroke";
var content_f20_49_21275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F52076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F52076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common medical complications of stroke",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Complication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Falls",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract infection",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest infection",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pressure sores",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depression",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shoulder pain",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deep venous thrombosis",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary embolism",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Medical complications of stroke were frequent in a prospective multicenter study of 311 patients followed weekly through hospital discharge and again at 6, 18, and 30 months after stroke.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Langhorne, P, Stott, DJ, Robertson, L, et al. Medical complications after stroke: a multicenter study. Stroke 2000; 31:1223.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_49_21275=[""].join("\n");
var outline_f20_49_21275=null;
var title_f20_49_21276="Diagnostic criteria for restless legs syndrome";
var content_f20_49_21276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for restless legs syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Restless legs syndrome (RLS), a neurological sensorimotor disorder often profoundly disturbing sleep, is diagnosed by ascertaining a syndrome that consists of all of the following features:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. An urge to move the legs usually but not always accompanied by or felt to be caused by uncomfortable and unpleasant sensations in the legs.*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. The urge to move the legs and any accompanying unpleasant sensations begin or worsen during periods of rest or inactivity such as lying down or sitting.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. The urge to move the legs and any accompanying unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. The urge to move the legs and any accompanying unpleasant sensations during rest or inactivity only occur or are worse in the evening or night than during the day.",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. The occurrence of the above features is not solely accounted for as symptoms primary to another medical or a behavioral condition (eg, myalgia, venous stasis, leg edema, arthritis, leg cramps, positional discomfort, habitual foot tapping).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Specifier for clinical significance for RLS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The symptoms of RLS cause significant distress or impairment in social, occupational, educational, or other important areas of functioning by the impact on sleep, energy/vitality, daily activities, behavior, cognition, or mood.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Sometimes the urge to move the legs is present without the uncomfortable sensations and sometimes the arms or other parts of the body are involved in addition to the legs.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     For children, the description of these symptoms should be in the child's own words.",
"     <br/>",
"     &Delta; When symptoms are very severe, relief by activity may not be noticeable but must have been previously present.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     When symptoms are very severe, the worsening in the evening or night may not be noticeable but must have been previously present.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the International Restless Legs Syndrome Study Group (",
"     <a href=\"file://www.irlssg.org\" target=\"_blank\">",
"      www.irlssg.org",
"     </a>",
"     ). Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_49_21276=[""].join("\n");
var outline_f20_49_21276=null;
var title_f20_49_21277="Declining risk of premature death";
var content_f20_49_21277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    The risk of dying prematurely declines as people become physically active",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 269px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Physical Activity Guidelines for Americans. US Department of Heath and Human Services. Available at",
"     <a href=\"file://www.health.gov/paguidelines/pdf/paguide.pdf\" target=\"_blank\">",
"      file://www.health.gov/paguidelines/pdf/paguide.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_49_21277=[""].join("\n");
var outline_f20_49_21277=null;
var title_f20_49_21278="Mag colon AP image";
var content_f20_49_21278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic endoscope imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) AP image of endoscope inserted to the distal transverse colon; note the 3-D illusion created by the grey-scale shading and the (electronically placed) rib margin (light and dark blue markers) and anal site (green marker) markers. (B) Lateral view of the same image; the purple sphere is the hand marker showing the site of assistant hand-pressure on the sigmoid colon loop.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher B Williams BM, FRCP, FRCS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_49_21278=[""].join("\n");
var outline_f20_49_21278=null;
var title_f20_49_21279="Acetaminophen metabolism";
var content_f20_49_21279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Acetaminophen metabolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 448px; background-image: url(data:image/gif;base64,R0lGODlhxgHAAfcAAL7IyLhdXevj3Q2T68/Pz6CgoP/69QCR8tXl5QGJ5Obc1bCwsACa//L9/er395BxcYCAgE6Hrf328t/f3wOE2ZCQkACh//Xt6KmMjJycnYsFBQd6xkh3l4yao8G8uYwzM/Dw8P8AALRvb4dWVk9mdQVWjMXW1qkREfry7i+NzP///zZ9rcnCvgCc/22ZtmZ2gQCU+RWI1ckZGX2oxm9vb4mVnRWEzoqMjuEaFOoCAq6trJe1yB9XfXuds5iiqBOU5Rd0s6u1t9DQ0ODg4NzTzHeJlmWEmACe/xdspiqBu4atyO3m4JwiIv/896Kvt8O5svQAAL+/v24fHgx0u9TNyE9PT9YEBBmDycQICCNol6OpqzVlhvj+/snGxO7u7lR9mlaYxdrV0URsiJiotDl1nt/r6/AJAxRgkSh0pwVqrUGPwlpyhLizsP//+6mmpWZye+Tw8MHNzXmTpJe80+QfGwJ+0ACT9niCiSF7tvQSDoufroWQl4ivypOIiJKZnQRwuERxjwua+ltCQgCY/fj5+H9HR/MNCLavq/Dp5Ctki7u2shlwq/759v/9+gGW+gCN883IxQCX+bm6urgyMs/b293Y1Q9/yPby7/0AAAWb/p6TkwmV8ej19X9ycuro5/bl2tfX18fHx/b29oRkZLS+v5+ZlgCZ////+X6huP/8+fz8/PkAAPv//yFuoQKa/1mBnwCa/PDs6QAAAP8BAUBAQMDAwH9/fz8/PxAQEC8vLzAwMACY/yAgIFBQUHBwcA8PD2BgYB8fH19fXwBepP///v7///7+/n2RngBuw+v19QCT/W53fMfDwa+qpu74+AKW9JeXlzF+sOgSEKmjnwOb/r+4tNcdHZuwvwiT3vT08w+Y8wCY/gCZ/f8EBMRaWoy10MHExAVEbcLHx5lBQahQULZHRxOO3/Lz87jExNry8oGJj2aSrnCLnoaBgFJugQad/7q+wL66uO/v78G2r8i+ufL5+URVYdDT1dTS0Ky/v/QTD2p/jp98fC5wnS5pkebl5CH5BAAAAAAALAAAAADGAcABAAj/AFUIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAMLHky4sOHDiBMrXsy4sePHkCNLnky5suXLmDNr3sy5s+fPRYdAgFBgsmjSkE+XrlxAFi9dsnSBgNz6dezZjGvDlm3a9ewKsoA9HuJbBXDhi4nz+h18MnBfAkHIwvX4efTpjK2rkE5dMgRZEAbK/5L1+Ht4geMZmxdPXvICWb0ECon9+H18FfN1MbYvn/5k2BAsANsCkAEooCwEMmbggJSBAAwusSX4mIMQ6iLhYhRGCNqGHHbo4YcghijiiCQKJkQtQwhUixAILTAaiwe5CAGLIKwoXy2zDVEABBWkiNaJPtoY44stElkjjCfmuGOPZgGpIowGyQhlQVJuJ2SSKujIo49r0VKcLLQYBAJs48lSS0FjlmlmLWAK5OWZXo6HC25mebmcCm2iSeZ4ZxKUZpm1sBmmCm8SWuacZdk5W55+7mmmnmoGmmehcU5HZ1pxhsfoQMAEBwIIFUypQqfAfBqqoG4+usCnsPVZ53iaDv9KEKmmikorqCdOqiqrj5KVKZ6ycuoprgXdeqquZ66apquYginLfMEKBOGlBU1LEJu8jMZLr6LhEq2vzkJrkLUIkauia9pyC4G3r3opbrWyUEuQuSpgm26f3X57lpfEeRlmpXi2NxDA6V2rJp/y0eKtvGLx6+y/ZQZcEMECn3twn0IoTAvDXjnsr6HpFTxwxCJbHGnCC7PlpQrftXlioCps2+enL58pc3Q1IkvQevuS13KYNcfcK82B2jx0zoMWOhDPY638M35FCz0zCEHfvB3SqTLLdLPbQfhta7j44gsvzKoAtthko2qozb6sK8tqr3a9qUBnj1123WnrzEvbEML/3TB5IHhtEN53T4e2pEk/urfbfqO1stlzC1TBtvBxOdDk4/UyhNqF9iLneT3THblxlGtuEOaVc/6o59OB3nR7remLuukFzb65zqzj4nqJvPfu++/ABy/88MQXb/zxYO0emfKNMT9ZxZJB75j0lFH/mPWLYR+Z9oxxj5j301sGvmHjdy/+85qVf5j6g7GfmPuEwQ+Y/OSfH3369m+Pf2X0+9V//PmDzP/aF8Dr7a966MPM1iCzQPWAxzIEyEUuCpALXYhqMRGcYAUveJgMUtCCk/mOLQZiiwc2poQjFAgKFyNCEprQMRkkQEEiCEKceEISxnBKDGcoQRk6BRTMsMkO/wlCQw4apoUqsEUVClJC572kEvZYhlNWmMQlEoSKTOnCLTLQhpkgUYlMfGEHe6iCCdwiFz4k4gZp4oEt1GEMTNmhGdFokCEqZQhJ+IM6LgETOZ4xjQMp4mGQWIFf0EAhTYwJI6CxiBYkAI5KoWIhD5kQLCIFjxagwBoq4RJCGhKRYgTMDuVRhWBEgSGCbEks9vGHIzDgkUkZZSlPuRA7GgWPDHDkFspmElmaEpVrBAwSF/ALYcjjIYlcCRHEQIEjmKIFFPABUqhITGMiUxYpNIoA0MCAZ0YCCdDo4kmGWcxjOiSZfBmlMH5xIYek8iSS4MEBWmAKUxwBGaUwijrZKf8RWwrlAjxwpikYcIQ03CEbJdlnOxvyTrwgMQrBqII5J4LOkTCiAkiIBD3rec98EoWKEJVoRSwZFIAKlKMUcAcRRvLQiE5UIhWlyxBp8IsKYKShH/HEG/5ggW7W057IaJxPZlrTm5JRKCjgwUZ/eoQD8EARICGqTS+C07gEI4URvMUENmILXoiECoBo5k9/yoAYwGMoVxVIVreqEVsEYygSiMBSf9qCSCzCD03wSFpVsFauerUuAhNGNjcywISwIRHPmCtZbeCBoQR2sBoprEok8ArF1pOgU7hDLDryWI9IliufZSJ6PiKBGgABFj4d62VTUAoWeOC1sI2tbGdLW9n/VgMfHwntFUfrERDEo7bADS5t52GETKh2rEegAAdWSliQpFC3WYEub6G7hBdswJXHJas2bMDd7nr3u+ANb3g3QILcgqQ90vVACWIg3va6N7zmoEZ26XqAREA1suflLV2kiyf9agQSYT3pfAfaggIb+MAITrCCFXyA8no2v/31yBOGYYEFW/jCCk7tgBnADSR0QAIZ4S967SJi/16EGM3IQmIHzOIWuzi7j3AwZyEs3Qlb4MU4zvFxCbqBFyACIyWO8H5prJFLmLYFGtaxkl8cY/M6ucYUXrKUX3yEBHDAiA8JMn+touWMCGANFLDslMes2iY/+MkfsTGZ17xjR2Th/xAW6TJgiXwRACdAwGzOs5lnjGYJRznPgGYALO4K4onIech9pkgbCpAFjQL60abYM0cOzRE1Q5rNubTEGgRgaDoj+sz0E8Ud/oDkSwNa0s1NdKX/bOo1V3kLkJAIpeUya4hcggQbuHGr2Yxq/Kp6I5be9ZjryoNqyNrTc6k1RCSwh9MmWdg67nWIkQ1sVkNbyVUGBBU6/eu4KBsixGCDP+Z57SVLG8jU1kiwy/1izN7hx9wGNYnTPREqiOHO7M7xuS/y7YusO98DrusioMGIivS7LQeHyCqngF2As3jfcaY3Rv7tcNU2dQuNjXi34cLfW5jYIqlgJCzEXPFIy3jSIP/xuJBXreuSWzylCkD3R1S+5ap0ls8bgUci8O3ysULc4AMR7Jk7QvGKEzQNReBYRG6O8rrgAqu50CpXu8MRIpBArCzexbV/TpFfQF3qbf1Fmq1d8hYMIgulaIRGnq7WqLM1I7ag+lyEoAs6qoCmU7VIVTMijyKkoeHZDcQABk/4whv+8IhHfAJOvhGpGtXuRC+B4BNP+cofXhuuGPCrQ8ERutsd70atoV1aKlKKxLQjqShFK0aeXQakoAZBcILsZ0/72tv+9rUfww1CAlKXjhSbISHAHWKP++Ibv/ZaeIVxd5zcNcTcI6R/aUROXxfPy1Ae61woMEUvki5sgeeqTUH/GPRJRuzzMyL+DEoTeuCIHTMACXso9EesrwLza7+WweQLOa15zlCORAHuEGbHJX7TBHwqUE3SB0qQNRTr135jVVdZMA0lsX8JWEn+txf0R0q/hH/cZxJGBgSl9lMEiBS+REsKkX4MyH7IZWWANBIZOEvbh2V74UmUhBDUZxLE4AaNtlQjmBSS9EkWuIBF0YCXdQQ9tgQqQYOg5ER+QX9z1IJ8lX8t0QWAwHM9GEtk9IR1dFRKQYQMwACLUAPylxJO+Edb2IGF8UVW5EJMmBLVdV2uN35NQUVgdEUGyBQNeATPkAhsABNqGEZtaCJ114J75xKlhQSmcIVL4U8oiBRN/4AKLVAHgIBbMUF/aoSGioFESXSBMnEIZ5AEcvgUWERSTJEKPZAGy3ABNaGJN7gYnvdBMhgTVFAFlAgVHsSFUOEL7SBONfGKUugdnGgTXnAOVEGKTqEKnqAKOtFAIWQZQqgeB5RA+pMZNfdpAhSN95ONmFGNySaNl8GNtOaNBTSN5PiN49gY4Dhn/COO69iO5XiOBqSN5uiO10iN8Jg92PiO4ZMZ+vIYKhcZ/Yg8AjmQBFmQBnmQCJmQCrmQDNmQDok8Q1ABW4IQBUALNAIMtAAdjyEPFWALFWBO8hAFPkQAUVCBYyEjq2I2FokSGTkxGrkWtaEw1vMdZ9IpviBUwP9iGATwC79wC7LwCzIUBbKgcj5pgmWRJrzwMTSJEqhBEKNjFuOBG+FRCxCQIlQpGmuyLVVZC71AC7RgU7VRlfXSlb6gdHURDLIgQwQgC28llEQpC0ZJFqQSHTZFk6JxJne5HRXglT0CAXjplyxTAEIQHiDgC7QADCwiGgtgmOfRlBBwmHlSkV95FtvCC8BQALOxlDRJkwXgNYMJDI/5Nr4wHRZpH6N5H3uxlrkwELmQlkJ5VW4Fl2hBLyyzJg/EJuHhJWKDC7hZLw80HemhC7ojnLcDJn2Tk6f5HWEymr7gOXk3FhlTJrKhmWaylI8DKr0AIDmpAp6TLn3hlgNRlEL/eTBxORbp8TQ02Zu4OR/IcTtT+Zv6gR+yAB3vUQG9+R6xogK48Fdtsp+j8ZReMRsgsAAyQ51U+SiPI5wVABz5aSijMRp9IQ8/ORC/IAshOZQCUZRo0SoR2SbpeZvg0Zvn8p4Nqp4hCqL5mSdtgi6jgZNfETa1sAC4MCfAoQsQUKAIil5kM5qaQjYd2gsxihx8QQOyUAVRUAWycEjgqQIaehbvwQsFABxhQpPzoTteEh4zugACUqWh2aD6STaekyskmpNesgCxw50huiNmAQylQyNeoguec6BwAjvjcaW1+SwsUzp/EZt7taRN6qRkogt1+SijaZkPJASss5yu0Sle/0p3rlEaJpqfQrAtH5MhuvOQmJqpmrqpnNqpnvqpRDEELekSo5owLvoQGXOqBkEDYKcTIVmeKVeDE8GqRWFGsroSpYoftKCqDZGqD2GYlgMTCmOWFrGUC7EpeWkRydoQ8hAM/5gTRIog1wSrDGELvLoQPlkUt/ALJokRxqoQyAqYyiquDQECSTkTbAI3kmlTg0kg7ZolhtkLC0CVQlAAZ8KVGQkCohocpTEEGImYAvGYnRIsebkjC9ALvTAleXmXd2mmBRsgCOtDBXALt5B3rUGtM4GWsiAMAxEFwnALwhCUVXALNCAPZrSxpcGqIBuUtrAAVSBRtnALq2GtZtOyL//rQy5bsXRjC1EAssfkky5bBT50pCR7TNZaAT4rE0KprhRrUwTQsnwFtUMQr/M6I/Y6lvm6r5eZJf8KIwIbrmdisAirsIDJsH7psIAptglLN3w5EK3BSywxmgPBnM5JKLypC8sROLqDkd8BIQECH6c5qbHhC0OACzY6oyqQnJvSm3YCG381or7pl8BJC4zrGrDxVkRKA0iad0mqE/VZoccklLkQsy1bpEQqtGiZC4d0VTT1ViX0C60JuxW6VRjqk8HQmm/1HlWQuUy6safbu7fLlgdoukUaMLmAlhwbE0Q6EJm7uUz6C1FwvPIgDzMKAXwLnH/bC4G7LbpAuIa7LtT/objBUrm28biRG7ls4jXk67iJO591ix4v+RJeORD+qZzbwQsQwiLAsRpYmSDdeaM+8yjHEZq1sJ/oMb4PlKAVE6lsopGVKxCwoQK/AJsYmqHPahPCIAsTkMGlgaRsNQFIaguxuYm0FAWsWqEkjCceV0KnVLvt0ZoqgKTHlAtil60qAMM2DMMhPMIYKqEX3BIUS6EU7HHNWqEytL8C0b8C8b/bUptnMsBvYsDbCbkKbDAk2sBU3B4RXL+MMr8x4cV4ki0tKhCd8lffaqxX+qBOXJugORr9csBWbCipEse4KaIPLMdsKcI0a8E5IaFDmbq9SxA+qccjxMLDWwULAMOG/4yhi+xxNpytj0wekRzIgTzIeqzC6PHDLBHE6AGbe5zBb7WJroLG4KHG1NnGVamiCJyb7fE4kFvHJnTHK8OiTUkoAZkSDzIQ3VkLatoaniMc+cHLvWCswAGkCyAc5rEiEVILvhCdZrq4CdzKFcOlV2rH0TzHIRwFBZBNxZQTwCFYtmDE3xwFIgwcRroAHItC5IxNC4CWKczIsunCGUoewFG6S1SU5kzJ2WrOUYDOmPzPMLFOA5HN2ww5SMqxa6kLwkzM8BGktemX+TGvzVymZzoQsjzNrVPNsXzNcrzLaiotQvoSbxsdD9I6QsAu31EaB1LKvZKnmZMl2xIfK60LQ/8guB9j0RztygJRqIxqzaw8x+b3kym0tDnRmubEu7HJT7FZvBOAlhKFu+7cyO/syO1hwzRVpD/LlkOZ1fOsQhq7RBVcwTBxsQIR1F63kyv8NgdIJv85yno6BDG91uNB0zYNzT8txwTB0yd6Hhe9HSV9qb55rSfxGmNxC6FMFzasFLfbNOYLE2wS0l2RwRjbFomdFEKZvF/RKXALqpzd2Z792aAd2qI92qRd2qZ92qid2qq92qzd2q792p9aBggw27Rd27Y92wqQ27q927zd27v9DzkE28NTDyOgAcZ93Mid3BogBSXQ3M793CUQDuEA3dRdAvuQV8ItPA4QACHQ3d7//d3gHQJ0YAHkXd7mbQHYYAnnvd6R8A3Ynd3As93hPd/eTQfPRlY/EAP3/VMHwAfvDd++I9/0Pd/2vWH5vd/11N//DeC8I+ADDt4FPl8McOAspuAM/jsO/uD1jeATrt8V7t8XHuDcreHfHeGtR+EDZuEh3uAjTuLdbeI7huLzpeIrTiIZTuIwrlodjuCmQOM1LiI3ruE5PlY7/uEL/uMfEuQPPuT47eEpDuJIDuQt7uJMflkynl0+HuUeouQDXuUDdeXHleVaziFcTt9eXuRPfuRjDhplTuAcDuaqJeZr/hltHt5nDudjJedz3hl1DuFv7uQzDuV7viF9XuJ/zuN6/z7omlHoG27ggI7lgq7onsHoL37oRi7pbD7lOG7paY7pdK7pQs7pga7mnn4ZlC7eog7ppF7qlXHqd/7oYR7prI4Zrp7qsb7qsy4Zte7oiC7rud7qoL7kth7nvv7rk7HrEo7n/F3sxh4ZyH7isE7suN7sjfHsMR7tec7s1O4Y1q7jyp7g2r7tjNHtRP7tPR7u4q4Y5N7kvT7t6Y4Y627l2L7s7v7uhhHvXz7v4F7v9k4Y+I7mo97vkPHv5p7oAn/vwd7lw57t/H7wgEHw+n7uDe/wfgHx7U7x457wZr7w9I7xi2Hxl+7xiQHynS7y8K7xbs7rIW/yCO/ijZ7sEW/wLP/fFyQf8DNfGDWv6jeP8yhv5xy/7zvv7z3v5ypf8kEfGDl/60cvGEkv7UuP9ENv6EVv809f8VH/8tB+8VVv9S5f6VOv81tP81fv9TCv9WG/F67eAlqX9St/9nlx6jhwBGt/7Wbv9ngB93Jf9m1v93aB93Pv7TGP7nzvFn6v90Y/+HVR+Gx/+Ig/F6cuDRbw9+Ue+BPf+GZx6oYQ+YZP9ZYvF5iv+YvP+Z0PF58v+ey+96NP+GMfAplv+vJe96mv+l3P+qBP96gf+2tR+psP9rgv+13f+ruv9L3v+y4P/KHP+yWhCoQw/ESh+8ev4wfgAmNIEv/QDvDG/EDh/MfVAj//YAMcbgcRoIoncQmAsA8ogP3Zv/rGf1wWUAdpQHIi+HYlIQFgUAdyUHDo3xPab3EJABAbWpgiWNBgizqkVCxk2NDhQ4gRG0oAw6DOnkYSNW7k2NHjR5AhRY4kWdLkSZQpVa4k6SBACJgxZc4MYcjCLoMGGQxIQS1nTgYHXDRhuREFGEctNvjIWNTpU6hRpU6lWtVqSpc0tca0ifOnKQab8Dj6ejCJgqsGIsAw1WJKAWJX5c6lW9fuXbwtX27V2rWsqUCtnjH4CzaBnqunOLBl0AJIkLyRJU+mXNmyxqx8aRo64vVrJg7mCBc2lQSUVcVswbZYxObya9ixZc/Wq3nz/82/775cGViYQQIjKKqmLsggUitwtJUvZ948cmbbXDv/HdQjwujCR+r4aEO1zTrVBBlwQ0MlJYEo6Sec9EXL+Xv48alCj15z+lcGMJR0OID9LwNLfCBKqjZ6CE88O8ioBKVbZHFQFhpMokUW+Sq08MLa6oPJL/xg4IMACnojrQVLikCEQBcOJKiFAzhAy6QGo5jAwYXkseWWKhZQIQpbFhCGFh1VaI8WYIRQYUIMk1RyyYboi47Dn/JTAhE1YPDvrxYSIEOLE59qI8WvjniEgyVglCUKAmQJZqFcfrElF1kIsEWWXxqUZQgVeIHAF1x4OZJCJgMVFD4nbYMSKBhmOP9ljASuxNKUDcgoIoowBLD0Ukwz1XTTJT4xsKwsvyiTJDvpJECFNG+xRRhZbJkzCiFlqUWFWtrDhUIkB9V1V9kK1YwzzxCdgRgBohmEtJyO4OYAG4ZBYwVoo5V2WmqrXSGJTLAETriRGqTBwVOjkEVVV3k8UwUIZF1All4W0AVXQHmVd97n9tIQ2LLym4EoH0JENkoLjhB4YIILNvjggUdMgB0Juj1zzmDkUeGXXwqIooICXkVX1nQhWIAXeOkVeeS5fOXrUJ0SJeqCCCJx9F+YY4YZoT0MEClGFeAUBtUqHAxmAY3TrQWEd3kB+U+Sk1YaKpO3Qrk4lRfqAogWXpb/+WqsD6qjgwGX9vrr+JruC7cO92XIhzpEzHptto+Ywgew45ZbObFvCzZlsxdq4pg6jmD777UtOIOeuQs3nLK6Z3pavKgZkqAICvwGfPJ/j6DAiIYP13zzku2tb3GwGmcIhSI2OMJqyinPMji6aPGFc9jjTlwm0PXtmiEDMkACBrVTTz3UWKwSeiEICoj9+KVn54rsKEV3iAUxIkfd96tDHRWiKKq4hQZ5bKxABe9VmIAGHBeYwJYoFjB+AmFuEUaIISYExvjiF6qAlnYXKsDjXnoxEnkAYkh5G2KesG7nkAvUoBUJOB31/sYiDghAIuuqwreqoII5FYBVBJAHxVZ1/wtx/WJcE/hFLmzxC1wIAWS6eJ0s3OMLWfiiF7LQ0YR4UbQA5rBCA7TP3aCWN4lUoggLhIXkHCgzFilIIz1zVTAAVQURfq8CsjCe+MQVIRVMURg34pisFuJCFeBCFyoAAbuQpoJ36VCN7+Fh7ZwXkTZUogMcmMImYGCB3h3xKy2IhD/Mo5EGucpV+nPQejS2EHHZYiFz2qItIDCE4akAjGCUpHtylas1ZpI2bbxP84DIkQtAogivWMQG7KgMHwLuZQxwBBogwZEpViF9OyNAnUoojzTlIgoFkGWrFpLLBUTBF0Lo2KzAOMMFpOt7l4yXJp35Gh6aoYB4O2BHUECEKP/4wB0cUEM3vflNcIZTnN1MQbZ0wgAkeMAjtnCiLKogjzbJQ1w7WwCcWpVIhtTTQboYwhBA1otKknGGuHjdGTH5TIQiznPRkWYqQ/fJkTThApuiaEUx9Qk9HIgBDACCJBL6UU1Gc5o/rGZkdmCH4jhGByBlqRpF6lDbXeakBSGRFrrTUpwi76X5eqNkZmqKIywlLjklKux2WraS5mWmCKmBzYr6VM3xEAojZRxEfWoH7RyDEVDlquGkStWHJhUvOxgEBRjWVQyBYH8VwBNKXFcVENQiPadqCHrWg6r0pEdiKgBaBe46m6/CtKd5IcYc6sA6tFpICLd6UEQo2ZHHSqX/Fg+SRS72WktfqqBU5/pWm37x19gElqdWjcwxSBC8xFoIZN8bwjAhMKtaQEAIBZCFnvB0v/yR8X60+J4L7wcMEKCrAMQkY3uKpD+PuQ4EwKDF/2rRC+U2ZLK3UEHPvpczBylSs7KogF7lQacsQmiTC7XNVAVL2rywYUGprZAQZDFGhgzBjDNsrSxw0VwYypCGf/IFnyT5XpABQ5KMRSMuIKALXODJhiC7b235yi4YApQh08WgL0/4Le02KBe3MJ64qOvh8WoIJuYdrVjvYgz2Wmiy7mnIhOQrYUqKkYzscq+AVYAnMJbRPe9diHtft65lUmiyEEDaDCEAgaNNWE0n/5TFBNIEtMzSwBY0EGEwx7WjKwOWvJohMVJTjFP54iK4N1YBbd8VJEqmmRZDboiaA0orWRCZzUiaM7yOfGTp0glHsJoTZbW7yFbl8sEX1LKIQ9BlT5r4y5kERm0hAAxckPFWkf4iL2oxBGQqM4y4WIC73jxJFofR0jM0Ep3jjLQp9qIWC7DxQijMkAmkh1XCWE8waEDlczlxAT2rYq+2fLJOGnDRLQUBn+xr40YXdGOyEAIIBlpQIcwQ1F/ccaiFULQqmprIuUKygyTs6iw7ZE7a7ZmaqkgAOP0Ci4UWsRvRO2yWvqut8G7Sr50G1pjSm6juDbW+F8LJ8yra3wP/aP8b8T1Ygie84PbuS7CpqfCRLYAWVVQrBNg6hFrMiowZp1XGNU7G/T1yIRj3+LyF8PGIVPziHN84bD3ukJPD/NIMqbjIJSKPjPk11rACX3p2lFdY5xy0enWIXRdCPtAW5aiJhji9QHDfHjPWQU/3Ysf+66AULtu+eErXg4g8hALcSiOLpSzVZ2V1ymYd7GKn+T4Z0vWtRwSzD+rgucZ9dVNt10G/2Ou6xMsQzGpXHsGgLtMYTpOGlrjp80pXW1d749dNURdP50VwaZRqWuHJyBsDRsa53liJPL614Z18nyxPIczDvSG0dVBbZ755iDjxe+MLr2V/EbH/hveCC+genHj/zio1NcSef6Ytz52ydGEvnle6YLF74duQou039ytuSKPp58Ijz5tGEXH+Q6KPZiE/dvsLQfAUlb0Q60NE0A6Bk66/SCEQi++Ehf9uFXoWpAtn9ovrVvrhZ5J4L1O+XTk1OOs3cDOj9zswKmKI7tM6L3o/iaA+h5gsBPwvBey18ZMvYJAvP2FAHsOecGMIcXEnhsguODm3W6gTiaGtAqAtWqKhu2OIWyi84/M/mQBAphNAXSHAMBuzeZuQj3MQWpg4hgi7ySMeAmyzZnKIHhw5hgDCEnQhIoxChoAhXpgQ6TPCMXuIGeG7hfgrnHm/Gew1QFMkOMkFe7IRytK/GTQ8/0PDweTTQUHhhW9rND2BtCd8wNxriCkiqPpJF1o4slnBOAd5PTGrPkfDw4WAQghsCEKUFTzpkyObIYDqQ1+on17wQoZglWBYlV+QwXNpRIawNSYrgFRxFTjxK1mTBVpjiF/YmacQrQCUw0CBtDErtklrNUbcwzx8EPeAu1MDRiLDhVZbCFw8tjwMwiUUxnUpqDKSBRDAQiEMI1hkCHnAtVcEReMbv4UoNzdRgW8JknXJBYaIQSwjQ5aQxRykRSaRr/OTC/eat7twr6S7i1tYEzcUMUSLQ3ZcknRBR6tIJskQSMlgFeOrQUPbx4frR4bcHHXkx4aMSNmxwZhQSJKSSP+MnMiEPLh3y0iP5JWHXMiPHEl6CcmLJEmUBEmKHDGOFLiUfMmwWclDa0mYrMklMcmqckmb3El20xCLzEmeDMqYNDR8mUWhPEq6kcmiXEekbMrQUkqadEqphCaoDLipvMrKADjFw0quzAuDs8quDMu60EqjFEuznA+ZhEORPEu2jArkW8u2jMt0TMuolEu7VIm3PMm73EuTyEug5EvAHAm/DKvALEyQwEnCNEzF3AjEzLfFfMyHaEyEg0zFlMyOpMzAtEydxEy71EzOxEzP/EzIDE3RXEzSLE3DPE3UDCBiKh48IQAOYxD+06zZvAvVnAs5sYUCWI8CuAW6KgnYRMf/7VlNlGi0+xI7fIKIQ3qI5AxBDAJIu7hNqDgfh2AVW6KQ5XSIBpEIjUnOcoRO4vwIMxszIsMn3Vyk3WwQYTAe8nGfU2EVVZGkW6gA95GY8+Qr7bkuHvGRWwiS7NmevVoJ6XwKcVm9ytorRdKY+9TNKHAi9AHHGRQGApgA9bQYCCEf7brPXZtP/ekR+6Or//SFLURNZHIIfMqycSEAJ8qFCOlEKluT9qMuB8kFJ9qZK6Ogb4mQOamTQsJREpzLjQRLqihQhrg/cTsXFOUwEYpNF709Fa0sGhjBFFzAG3WnHN2uYGi/QfuWb8NMuKsFIKRA+POlJK0wnosC8hEhLNOu/yv7Lhmlrp6RmDYxU3A8EyZipyVEiQFlic3ypRgZQexE0sK7su1EpDQNVFjBp3VRpCuL05z5xEKFk+pqFVtIMs4kuaGBIQiIKxo50UGlLo2hIH1a0y/6VPncroXYTgU9k0ASpP4L0q2UCvSYIvWoU1uQJxrRmDItVFGV1O70JU9FVVQt1O1sVTwjziHABQOjQFIVIRqAzwpDn3FbACfCshw51VO9sinqERJc1Ytxp1l6VX2sy6kg0i/0oBGkU2eF1gZZADlpFWoNVPTBp2DdVgoS1u2MpfQpRtSMNgfhBQHDpwKgmG+hrglwondqv2rdrk8s0yzDtXeiUwVtJ0ITUP+Z/MnEpArYLLpyC4ad0ZiBVbcbjSJ4UpNqPVhwBVYyLTyIlRhiBRQ8rcDwVJo9nVm2rFmbNUuczdmw3Fme5Uqf/dmrDFqhlUqiLdqmPFqkPUqlXdqgbFqn3UmojdqanFqqfUmrvVqUzFqtHUmu7VqP/FqwxUixHduILFuzZUi0TVt2XFu2lUO3fVsBjFu5XTy6rVuIu1u8TTge0ocWENK9lVqZzIO/jdXAtUkeIlzAPVyYTNzCLUvGTUnHXdzI3drBfVymrFzLNTTFNVzNJcnJ9dzP/cjQhdzRzcjSzdzTRd3LpdzVlcjUhcjXhd3WFd3ZbcjYhcvbxd3aNd3dbdv/3lXd3wVezsVc2R1eWsxdvUTeflTev2Te5g3e44Ve5etb49Vd6q1e6cXe7G06583Y7p3b7V3e8LXb8X3e8jXf4nXd9CW473XM9s3b8wXf+OXb+YXf+nXf+53M/B229+Xf/v2y/73MAA6Uc5DHyuCE+TUFAC4KQvCEAr6LMqgCN4ANBGACQ/PbwtiFCMgcqwABGvjNCL6KUPiAE+gC2BAHLHhDhzOIXVgBbrGKJogAf5CgEa6KYvABJsAEGQgF2OCHHIBVULmCP7IKAwCDBPgCG77hqBAFCDgBmOjh1yiDcTC0mgCrtkiAMZCLI96FBFiDLjEJopOnelyJ9tiIk3O9//+5sVpYY0yVx9h6LWP0uKGxSwQYASuIiROIg9eAhhU2NDq4XheGgQiIYao4YmU4gm05CQe5IO/kiOzciP3ZCBuyvFB7F2hEwgdBNgCTBQETUz1kS3T4gCCOCQ0wgcsogw+w4hA4ATuYHga4AhQ24ld4BAbQjn3w4JF4kPTILPq81uekT2GQBwplReMhgPbhniy61Sza1EmGPPwJkkV0ECKjJPlykCrqGBAAmdlCwBmqIm48S1YoACaAgpk4Zcsohk7IY0ObhXF4hDzSiUdYB12WCkao5b/Nqq0iicq6vUWtUxow0hmt0SdlURIyoRLCsvXkLqR5OgNjrhZzIWajJP8YMjMk3DZZKdEHg7E8DUtnaIcTmAWaQOfKKIA/NrQc4AdLiOeDsASUs2d8JoiguoGmEIlxoa1AmhhyrL9TdVM6nSId+ZZTmaJfkDAkmaIqkkcXk2gWM5o8uZONcR0HY0QJDOewvGN2pokToITK0AIoZmUZcIMrmJ7QIYMlhml4Fg+38YGhCglCzS5svbIy9VY6nZEFRJpIcggk6Tr3WJfjjKGNucINVIFGuy7zE8XjwTjXe2m8KIDmMolRLmWtmAQEmAwuwICvZuUPgIMI6A+FMYILoIom6AHPLgi3qWCb/jC4vr856S1THTc0Addg+ER4qpOsQxLnq4UC6FIkoTr/9zCyPbGvjSGy+FLWFlTWIeBUWRlRzrE6XhyJg3KIvOaI2ELgj+CCUmCCVdAMypYMShiFk7ZiK+gDFWAUss5iIwhjqGgCVHjlc3qM1F4IVlEkeegZdStV/EbZCyqAFX3PM5EHMYpGQHEXao5oQqKFMnq+M3NuBsRCXTASUGZszXHu7Xuu6NofMAUuWoEu3qIVkJHjBYAu1pIf4yk2IjGSZEJx2apuaM6tjeCETgjvrejuu2AFBOgDJpBsVmYCrr6HK5iZBOCALripp2Bv99YJ1lAnsMltCT8eQDwyGlmXXoiwPwEGKn80CJiQ43ahApDy/FKh93odBDuwBHs6XagF/1wAKKFx6EczQIgABTyuj3IoA7ooBi4oAx14ACawAkxg5ZiwgnZYCEaIAJT6lxaAASDYB0gwgLZeCSN3FAYYhFaY5a+BIYZWI2CkEeA+mlxJIxCogF54F4xeiBkKLgTbmFnxsQf7HvcyPVRHaifUiHz4AHOuD3LIhzgAAF3fdV7vdV//dWDXdXTQggLAgEJgAhnQcT8PgQ+g84WQhJWGmVtOADwABD1wAw9gAW3fdm7vdm//dhY4hk1YpUjohyL2UgKkkQm5s1FHmvKbonZnJlSHMzkjwABDwtgK5YjgggzYYQ2ZBWmQAYEfeIIveIM/eIQveCywghwQ6WWfiROADP/H+YIj/5eNaoFHQAZLuAKO73iP/3iQD/kriAFz2qMEWS90J+7LY5dVEzAgxLzaqpVTm5AFEAJ4l/LhnpU+eS5mI2x2WUChye3djgg4AO+HP3qkP/rxfohaiParueUWiHqpn3qqr3qrl3rSCAoXmQwhmEJapHBA6TYzsiEXCi7WW3e+upXvMbZeCC5/MqNrqy3joa1tS6HhIfAkbAhKKISsTnq//3vNsIJR4IKHMAA5SACW1iPAsR7JgKQm94jo9rfIn4wgoHXAv3zMlwnBh4OIUAAyGITzVnysCRX1TgleAtBrdE/0FGZiFkThIp5sdp36sfAOr4UPhy3oElF4m/z/vCAETQjpzA9+wN98jagFqgl90Ueiy7mElZiTKmCnKGiTN/ms/6JRViQAUf+0F2IXQEQXYMhyKgo7LvdymRVlKehz4U//oz+BPiAEjtCBRaia5KeeIziDaliJ26uRK1r1ngYIWbdU1JIFQYUsWioQKpTFa2FCFSAq9NJlUAUtWQt7GYTAS+PCkCJHkixp8iTKlCpXsmzp8iXMmCZJfcgR4ibOnDp38uzp8yfQoDxzfNBSbCUxN0BaMDDl9CnUqFKnUq1qNWqLDX7ayCwpMGQUWbZUhB37FeHAggcjMmzbVheuChUuZlyYEQLeg1338u3rdyUEWgq7DqklZKGQWiFB/9RSvJBx48Mhh+AtELJx4yEmEYywIvQz6NCiea46MQrBSx2tIrW46vo1bKpHLHVo9HdhFVkVolSJ8isYb1kE0EJMexGXLF/AIlpcUCCiw1q+6MpaIGRur1oLgN3u7v07y+e99MqEIEvW4boLp1dfWPC8LF0gVDznZVE+QvjkSTrrdGI0gAEKGMIqWBQSBBcxQSIGBUfE9iCEVLVAQRGMeCePML/IEswEBOSyoWXEEacWfbjgMp1CQnyUkULPJXTRAshVoIJH5/UCHo45gjdERsA0BoEQBShWSy+0+DIfCIH1ssBI5kWkngofycIdQRFxVMEQDs03F5UZOXYSF24wAf/FgGWauRMUJxSiRTJ7LXEHEDA4GCGdsR1BATuX6NhSFNPNWJJ2tZjny56FGmqoivEVYB5yECwgSy/T3QgXBBZJtpB5GVWg3qMVIDdfQQqZB8FchEokCy52yfIlSgDUdCasAlrBxAhBtNkXMR5wsMEgRzRVJ7BTHZHAPigcqtJ5tMxXkou4ALPssdFK25d5ipnHpAoc4fWREAlBsNx+1fKCi0ULLTfEcpYVxAsEyFF2EUQgeckSAqNgESu+QXUz6wiamJBgdygswMEUB7TAVLAJD/tFLNM6/DDE0lZL46qq5gVBqHmxWu17GoGQ7Ee6VIkLLdnRByli8anKakoN3HD/wiz5yhzCLDlgIcMHI7gRB8A4isJCEWRYkoCvDByc8IMtPCKGABE7/TTUf008sQrYacediUJWECKmFWekEZd4IZcYWyFZ5GhzBFmEZUvFaMGETT91gwndddt9N9556113CFDkYIUV1kzCxDj8+IEOHEcdG8shHQDSSgx1UGDHNoNYfjnmmWu+OTW/QtXCAWQogNIEt9DgtJEiCUEL1zKt3npKvtCiWdS1d21txZhKeaMQHDmE7e0qZKmRRctO50uoI4GwHKrYwgdvSyYUEndPk4hwPfbZa789991nzw8G7WQgCSVwNMBKxMZIIEAUFezRgwvxyz8//fXb70IEgUTF/0AkZBCR0i1+IQ8c2UIWUUDWYBZCGZbBZIEtAQEvEmi7CULNRAsAXlfKYC+fBCAdXGgACEMowhGSsIQmBGHPKBiSVEighS58IQxjKEMDXOMAnmOAI8iAj5SEhWsFuMUtZkQAWzBpiEyaAA1uUYUFRMEWBCjAAXljOnmUThbCsMwEhHELYUgmMMuRoAMXtYBe9OJSwsPYGWuxQOeE0VFklEwBBPOnkzFQhXY8VgGQc6O+NKACMONJADhxx0GypA07sKFTGMCAVrBAJTQAiQoeSYPczCiAUchFMOQhj1/8whZaLKCGiCiLKjyyCgQIhixyQYMJ/CIXtvhFqiSVKZGQKP8j9nEILS+iloIghxa1dIhFHnK8K4UkOYQ8JjJLEoRX6SSQyXymSAyJSAbAAg8HVAkQQ/IbWxRwIPIIhoaGM5cQTaCA2MoNN1GpggIecC7CsMUtVoWLh7jFPdRZSLkuo0uDFMRUv8SnRuaJl7IJBpoGJSQlCuGZnDjzoMmUpiJbsAhFsCSbEAkGN20RImFsaCHsDMlHVRDPjI7lowV8py0gkKXBlK1KB1EPlFzqUhLJFKYacUheuFZQh/J0gnB4gAwYKsieEhKiLQCCFlqSoZCgMwoFGMtzciMMFRAglU6tQkjn0psFTLWAtohCVXPBRF+srjrPkeA/MQJJFXQLF4H/4Se80loXbdViUSFxFlHzCjUuZIAJmLhJQ/WqQmkeYQpaIEZLnnNNDGmokwT4xUAKaJkFfEgsIV0nKkepggmgsgoqoOx5dDGERLEoly+V11pVMB1egIumcvUYMJDjVnvCTrC2jRZNbBLY29bOkM/YQG1eEoxc8JYvtKBncZNrqAl0xhtDVe7T2jCHP+yBKy8Jy1Sh65Ll1FG73vVLMjohiHN812l7eIOFyqve9SaTC+AQBXunZQxQeCK+9r0vfvOr3/3yt7/+/S+AAyzgARO4wAY+MIITrOAFM7jBDn4whCMs4QlTuMIWvjCGM6zhDXO4wx7+MIhDLOIRk7jEJj4xI4pTrOIVs7jFLn4xjGMs4xnTuMY2vjGOc6zjHfO4xz6eVkAAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    At therapeutic doses, 90 percent of acetaminophen is metabolized in the liver to sulfate and glucuronide conjugates that are then excreted in the urine. One-half of the remaining acetaminophen is excreted unchanged in the urine and one-half is metabolized via the hepatic cytochrome P450 (CYP2E1, CYP1A2, CYP3A4 subfamilies) mixed function oxidase pathway to N-acetyl-p-benzoquinoneimine (NAPQI), which is hepatotoxic. With normal doses (blue arrows), NAPQI is rapidly conjugated to hepatic glutathione, forming nontoxic cysteine and mercaptate compounds that are excreted in the urine. With toxic doses (red arrow), the sulfate and glucuronide pathways become saturated, resulting in an increased fraction of acetaminophen being metabolized by cytochrome P450 enzymes. Once glutathione stores are depleted, NAPQI begins to accumulate and hepatic injury ensues.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_49_21279=[""].join("\n");
var outline_f20_49_21279=null;
          